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Abstract
Genome-wide association studies have become a standard tool for
disease gene discovery over the past few years. These studies have
successfully identified genetic variants attributed to complex
diseases, such as cardiovascular disease, diabetes and cancer.
Various statistical methods have been developed with the goal of
improving power to find disease causing variants. The major focus of
this dissertation is to develop statistical methods related to gene
mapping studies with its application in real datasets to identify
genetic markers associated with complex human diseases.
In my first project, I developed a method to detect gene-gene
interactions by incorporating linkage disequilibrium (LD)
information provided by external datasets such as the International
HapMap or the 1000 Genomes Projects. The next two projects in my
dissertation are related to the analysis of secondary phenotypes in
case-control genetic association studies. In these studies, a set of
correlated secondary phenotypes that may share common genetic
factors with disease status are often collected. However, due to
unequal sampling probabilities between cases and controls, the
standard regression approach for examination of these secondary
phenotype can yield inflated type I error rates when the test SNPs
are associated with the disease. To solve this issue, I propose a
Gaussian copula approach to jointly model the disease status and the
secondary phenotype. In my second project, I consider only one
marker in the model and perform a test to access whether the marker
is associated with the secondary phenotype in the Gaussian copula
framework. In my third project, I extend the copula-based approach
to include a large number of candidate SNPs in the model. I propose
a variable selection approach to select markers which are associated
with the secondary phenotype by applying a lasso penalty to the
log-likelihood function.
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ABSTRACT
Statistical Methods in Mapping Complex Diseases
Jing He, Hongzhe Li, Mingyao Li
Genome-wide association studies have become a standard tool for disease gene
discovery over the past few years. These studies have successfully identified genetic
variants attributed to complex diseases, such as cardiovascular disease, diabetes and
cancer. Various statistical methods have been developed with the goal of improving
power to find disease causing variants. The major focus of this dissertation is to
develop statistical methods related to gene mapping studies with its application in
real datasets to identify genetic markers associated with complex human diseases.
In my first project, I developed a method to detect gene-gene interactions by
incorporating linkage disequilibrium (LD) information provided by external datasets
such as the International HapMap or the 1000 Genomes Projects. The next two
projects in my dissertation are related to the analysis of secondary phenotypes in
case-control genetic association studies. In these studies, a set of correlated secondary
phenotypes that may share common genetic factors with disease status are often
collected. However, due to unequal sampling probabilities between cases and controls,
the standard regression approach for examination of these secondary phenotype can
yield inflated type I error rates when the test SNPs are associated with the disease.
To solve this issue, I propose a Gaussian copula approach to jointly model the disease
status and the secondary phenotype. In my second project, I consider only one marker
in the model and perform a test to access whether the marker is associated with the
iv
secondary phenotype in the Gaussian copula framework. In my third project, I extend
the copula-based approach to include a large number of candidate SNPs in the model.
I propose a variable selection approach to select markers which are associated with
the secondary phenotype by applying a lasso penalty to the log-likelihood function.
v
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Chapter 1
Introduction
For most common diseases, including heart disease, diabetes, hypertension, and
cancer, multiple genetic and environmental factors jointly influence an individual’s
risk of being affected. Rapid advances in SNP genotyping technology and the depo-
sition of millions of SNPs into public databases have set the stage for genome-wide
association studies. Most of these studies have used a single marker based analy-
sis strategy in which each SNP is tested individually for association with a specific
phenotype. There is a growing evidence suggesting that complex diseases are the
results of marginal gene effect and the gene-gene interactions (Moore and Williams
(2009)). Detecting such interactions will allow us to elucidate the biological and
biochemical pathways underpinning complex diseases (Moore (2003)). However, de-
tection of gene-gene interactions has long been a challenge due to their complexity.
The standard method aiming at detecting SNP-SNP interactions may be inadequate
as it does not model linkage disequilibrium (LD) among SNPs in each gene and may
lose power due to a large number of comparisons. To improve power, in Chapter 2,
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we propose a principal component (PC)-based framework for gene-based interaction
analysis. We analytically derive the optimal weight for both quantitative and binary
traits based on genotypes and pairwise LD information. We then use PCs to sum-
marize the information in each gene and test for interactions between the PCs. We
further extend this gene-based interaction analysis procedure to allow the use of im-
putation dosage scores obtained from a popular imputation software package, MACH,
which incorporates multi-locus LD information. To evaluate the performance of the
gene-based interaction tests, we conduct extensive simulations under various settings.
We demonstrate that gene-based interaction tests are more powerful than SNP-based
tests when more than two variants interact with each other; moreover, tests that
incorporate external LD information are generally more powerful than those that use
genotyped markers only. We also apply the proposed gene-based interaction tests to a
candidate gene association study on high-density lipoprotein cholesterol (HDL-C). As
our method operates at the gene level, it can be applied to a genome-wide association
setting and used as a screening tool to detect gene-gene interactions.
Another problem in genome-wide association studies is the analysis of secondary
phenotypes. Many genome-wide association studies measure a variety of quantitative
or qualitative traits other than the disease trait that defines the case control status.
Exploring these secondary phenotypes can maximize return considering the massive
time and money invested. For example, recent genome-wide association studies for
height (Lettre et al. (2008); Sanna et al. (2008); Weedon et al. (2007)) and body mass
index (Loos et al. (2008)) were conducted using samples from multiple genome-wide
association studies which were originally conducted to find markers associated with
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risk of diabetes, breast and prostate cancer, and other traits. In addition, examination
of these secondary phenotypes that may share common genetic factors with disease
status can yield valuable insights about the disease etiology and supplement the
main studies. However, due to unequal sampling probabilities in cases and controls,
standard regression analysis that assesses the effect of SNPs on secondary phenotypes
using cases only, controls only, or combined samples of cases and controls can be very
misleading when the test SNP is associated with the disease status. To solve this
issue, in Chapter 3, we propose a Gaussian copula-based approach that efficiently
models the dependence between disease status and secondary phenotype. Through
simulations, we show that our method yields correct type I error rates for the analysis
of secondary phenotype under a wide range of settings. We further show that the
type I error rates of our test are under control even when the model is mis-specified.
To illustrate the effectiveness of our method in the analysis of real data, we applied
our method to a genome-wide association study on HDL-C, where cases are defined
as individuals with extremely high HDL-C level and controls are defined as those
with low HDL-C level. We treated four quantitative traits with varying degrees of
correlation with HDL-C as secondary phenotypes and tested for association with
SNPs in LIPG, a gene that is well-known to be associated with HDL-C. We show
that when the correlation between the primary and secondary phenotypes is >0.2, the
P -values from case-control combined unadjusted analysis are much more significant
than methods that aim to correct for ascertainment bias. Our results suggest that
to avoid false positive associations, it is important to appropriately model secondary
phenotypes in case-control genetic association studies.
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One disadvantage of single marker based analysis is that the obtained P -value
may not be significant when adjusted for multiple testing. An alternative approach is
to impose a lasso penalty to the log-likelihood function to select the relevant variants.
The lasso penalty is an effective device for model selection, especially in problems
where the number of predictors far exceeds the number of observations. In Chapter
4, we extende the copula-based approach to include a large number of candidate
SNPs in the analysis of secondary phenotypes. A Lasso penalty is applied to control
the sparsity of the solution. We proposed an efficient computational algorithm using
the coordinate gradient descent method to solve the likelihood. For a given value
of the tuning parameter, the penalized likelihood is maximized by the coordinate
gradient descent method. This method is compared with the ”Penalized” package
which uses the regular lasso assuming the secondary trait is normally distributed.
We test this method on both simulated data as well as the LPL gene on HDL-C
study. We demonstrate that the copula-based approach is efficient in controlling the
false discovery rate.
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Chapter 2
Gene-based Interaction Analysis
by Incorporating External Linkage
Disequilibrium Information
2.1 Introduction
With continued decreasing cost of high throughput genotyping technology, genome-
wide association studies (GWAS) are becoming increasingly popular for gene mapping
of complex human diseases. Most of the published GWAS papers report results from
single-marker-based analysis in which each SNP is analyzed individually. Although
this simple approach has led to the discovery of disease susceptibility genes for many
diseases, the identified SNPs often only explain a small fraction of the phenotypic
variation, suggesting a large number of disease variants are yet to be discovered.
There is growing evidence that gene-gene interactions are important contributors to
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genetic variation in complex human diseases (Cordell et al. (1995); Cox et al. (1990);
Howard et al. (2002); Moore and Williams (2002); Xu et al. (2004); Ochoa et al.
(2004)). However, detecting gene-gene interactions remains a challenge due to the
lack of powerful statistical methods. The most commonly used statistical approach
for studying gene-gene interactions is to use a regression framework in which a pair of
markers and their interaction terms are included as predictors. When a large number
of markers are available, one might consider doing a stepwise regression (Hoh and
Ott (2003)) or a two-stage analysis (Marchini et al. (2005)). Although such methods
have been proven useful in simulation studies, they may lose power when multiple
interacting variants exist in each gene.
One potential solution to the aforementioned problem is to perform interaction
analysis at the gene level. There is increasing recognition for the importance of
gene-based analysis (Neale and Sham (2004)). Several methods have been developed
to test whether a gene is associated with the trait of interest (Gauderman et al.
(2007); Wang and Abbott (2007); Wei et al. (2008); Li et al. (2009)). The central
idea of these methods is to summarize marker genotypes into a few components so
that the overall degrees of freedom are reduced while most information in the data is
retained. Extensive simulations demonstrate that gene-based association analysis can
increase the power of detecting genetic association compared to single-marker-based
analysis. It is therefore reasonable to expect that gene-based interaction analysis may
outperform SNP-based interaction analysis and lead to identification of novel disease
susceptibility genes.
Recently, Li et al. (2009) proposed a novel gene-based association test - ATOM,
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by combining optimally weighted markers within a gene. For each marker in the
gene, either genotyped or untyped, an optimally weighted score is derived based
on observed genotypes and linkage disequilibrium (LD) information in a reference
dataset such as the HapMap (The International HapMap Consortium (2005), The
International HapMap Consortium (2007)). To reduce the dimensionality of the data,
ATOM tests for association using selected principal components (PC) of these derived
scores. Simulations and analysis of real data showed improved power of ATOM over
methods that do not incorporate external LD information, especially when the disease
loci are not directly genotyped.
The success of ATOM motivated us to extend it to the analysis of gene-gene
interactions. Here we describe a PCs framework for gene-based interaction analysis.
We analytically derive the optimal weight for both quantitative and binary traits
based on pairwise LD information. We then use PCs to summarize the information
in each gene, and test for interactions between the PCs. We further extend this gene-
based interaction analysis procedure to allow the use of imputation dosage scores
obtained from popular imputation software packages MACH (Li et al. (2009)) or
IMPUTE (Marchini et al. (2007)), which incorporates multilocus LD information.
We evaluate the performance of the proposed tests by extensive simulations and the
analysis of a candidate gene study on high-density lipoprotein cholesterol (HDL-C).
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2.2 Methods
We consider the problem of gene-based interaction analysis between two genes with
multiple markers in each gene.We first present the analytical solutions for quantitative
and binary traits assuming the interacting trait loci are known.We then extend the
method to the more realistic situation in which the interacting trait loci are unknown.
2.2.1 Quantitative Trait
Suppose the quantitative trait of interest Y, is influenced by the interaction be-
tween two diallelic quantitative trait loci (QTLs) located in two different genes. Let
Tj and tj (with frequencies pTj and ptj , respectively) denote the two alleles at QTL
j (j = 1, 2). Assume the mean of the trait value Y given genotypes gT1 and gT2 can
be written as
E(Y |gT1 , gT2) = αT + βT1gT1 + βT2gT2 + βT1,T2gT1gT2 , (2.2.1)
where gTj ∈ {0, 1, 2} is the number of allele Tj at QTL j. To detect interaction between
the two QTLs, we wish to test H0 : βT1,T2 = 0. However, as gT1 and gT2 may not be
directly observed, the test of interaction is often accomplished through examination
of genetic interactions between genotyped markers. Assume a diallelic marker j in
gene j (with alleles Aj and aj and allele frequencies pAj and paj , respectively) is in
LD with QTL j. We will show that the mean of Y given genotypes g1, g2, at marker
1 and marker 2 can be written as
E(Y |g1, g2) = α + β1g1 + β2g2 + β1,2g1g2. (2.2.2)
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Equation 2.2.2 allows indirect assessment of interaction between the QTLs by testing
H0 : βT1,T2 = 0.
The regression coefficients βT1,T2 and β1,2 reflect the magnitude of interaction be-
tween the QTLs and between the markers, respectively, and their relationship depends
on the degree of LD between the QTLs and the markers. To explicitly derive their
relationship, we note that E(Y |g1, g2) can be written as
E(Y |g1, g2) =
∑
gT1
∑
gT2
E(Y |gT1 , gT2)P (gT1|g1)P (gT2|g2)
= αT + βT1H1(g1) + βT2H2(g2) + βT1,T2H1(g1)H2(g2),
(2.2.3)
where Hj(gj) =
∑
gTj
gTjP (gTj |gj), j = 1, 2. Li et al. (2009) have shown that when
both the QTLs and the markers are in Hardy-Weinberg equilibrium in the population,
Hj(gj) = 2(pTj −4j/paj) + [4j/(pAjpaj)]× gj, (2.2.4)
where 4j = pAjTj − pAjpTj is the LD coefficient between QTL j and marker j. There-
fore,
H1(g1)H2(g2) =4[pT1 −41/pa1 ][pT2 −42/pa2 ]
+ 2[pT2 −42/pa2 ][41/(pA1pa1)]× g1
+ 2[pT1 −41/pa1 ][42/(pA2pa2)]× g2
+ [41/(pA1pa1)][42/(pA2pa2)]× g1 × g2.
(2.2.5)
If we replace the items in 2.2.3 accordingly by those in 2.2.4 and 2.2.5, it becomes
apparent that 2.2.2 holds, with
β1,2 = [41/(pA1pa1)][42/(pA2pa2)]× βT1,T2 . (2.2.6)
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Equation 2.2.6 indicates that the two interaction coefficients βT1,T2 , β1,2 differ only
by a factor [41/(pA1pa1)][42/(pA2pa2)], which is a function of the marker allele fre-
quencies and the LD coefficients between the QTLs and the markers. The above
derivation can be readily extended to binary traits such as disease affection status
(see Supplementary Material).
From the above derivation, we can see that if we define a weighted genotype score
at marker j, g∗j = [4j/(pAjpaj)]gj, then the corresponding mean model for Y given
the weighted genotype score becomes
E(Y |g∗1, g∗2) = α∗ + [βT1 + 2βT1T2(pT2 −42/pa2)]g∗1
+ [βT2 + 2βT1T2(pT1 −41/pa1)]g∗2 + βT1T2g∗1g∗2
= α∗ + βT1g
∗
1 + βT2g
∗
2 + βT1,T2g
∗
1g
∗
2,
(2.2.7)
with the interaction coefficient being the same as that in equation 2.2.1. This indicates
that for any pair of markers with one from each of the two genes, using weighted
genotype scores will result in models that share the same interaction coefficient βT1T2 ,
a fact that we will use below to combine multiple markers within a gene.
Suppose mj diallelic markers in gene j are genotyped, with alleles 1
(j)
lj
and 0
(j)
lj
for
marker lj(1 ≤ lj ≤ mj) and allele frequencies p(j)lj and q
(j)
lj
, respectively. The above
derivations suggest that for individual i(1 ≤ i ≤ n) and marker lj(1 ≤ lj ≤ mj)
in gene j, we may consider the weighted genotype score g
(j)∗
i,lj
= [4(j)lj /(p
(j)
lj
q
(j)
lj
)]g
(j)
i,lj
,
where 4(j)lj is the LD coefficient between QTL j and marker lj in gene j, and g
(j)
i,lj
denotes the number of allele 1
(j)
lj
carried by individual i. Then the mean of the trait
value Yi given weighted genotype scores at marker l1 in gene 1 and marker l2 in gene 2
will be E(Y |g(1)∗i,l1 , g
(2)∗
i,l2
) = α∗l1l2 + β
∗
l1
g
(1)∗
i,l1
+ β∗l2g
(2)∗
i,l2
+ βT1T2g
(1)∗
i,l1
g
(2)∗
i,l2
. When all possible
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marker combinations in the two genes are considered, then all m1 ×m2 interaction
terms share a common coefficient βT1,T2 . This suggests that for individual i, we can
aggregate the information from mj markers in gene j by defining a score
S
(j)
i =
1
mj
mj∑
lj=1
4(j)lj
p
(j)
lj
q
(j)
lj
g
(j)
i,lj
=
1
mj
mj∑
l=1
w
(j)
lj
g
(j)
i,lj
, (2.2.8)
and then assess interaction between the two QTLs by examining the cross product of
their scores S
(1)
i × S(2)i . In situations in which the trait locus is in complete or strong
LD with a genotyped marker or is itself genotyped, the score in equation 2.2.8 may
not work well as the other markers will simply add noise and dilute the association
signal. Given this consideration, an alternative weighted genotype score is
S
(j)
i = w
(j)
lj,max
g
(j)
i,lj,max
, (2.2.9)
where lj,max is the genotyped marker that has the strongest LD with the trait locus
as measured by r2.
2.2.2 Estimation of Weights
In the previous sections, we assumed the trait loci are known. In real data analysis,
the locations of the trait loci are unknown. It is reasonable to assume that each of the
known polymorphisms in the gene, either genotyped or untyped in the study sample,
is equally likely to be the trait locus. For each such locus, we can estimate the weights
for all the genotyped markers and calculate a score for the locus. Following Li et al.
(2009), we propose to estimate the weight using LD information obtained from a
reference database such as that generated by the HapMap, other publicly available
11
dense SNP data sets or resequencing data from a subset of the study sample. Suppose
Mj markers are available for gene j in the reference data set, and they are a superset
of the markers genotyped in the study sample. If marker kj(1 ≤ kj ≤ Mj) in the
reference data set is the trait locus, then the weight for marker kj in the study sample
is
w
(j)
kj ,lj
=
4(j)kj ,lj
p
(j)
lj
q
(j)
lj
, (2.2.10)
where 4(j)kj ,lj is the LD coefficient between markers kj and lj, and p
(j)
lj
and q
(j)
lj
are
allele frequencies at marker lj in gene j. These quantities can be estimated from the
reference data set. For individual i and each marker kj in the reference data set, we
can calculate a weighted genotype score
S
(j)
i,kj
=
1
m
mj∑
lj=1
w
(j)
kj ,lj
g
(j)
i,lj
, (2.2.11)
or an alternative weighted genotype score
S
(j)
i,kj
= w
(j)
kj ,lj,max
g
(j)
i,lj,max
, (2.2.12)
where lj,max is the genotyped marker that has the strongest LD with marker kj.
We note that the weighted genotype scores in equations 2.2.11 and 2.2.12 share
similarity with imputation dosage scores, and they can be considered as a simple
version of the multilocus LD-based imputation dosage scores obtained from software
packages such as MACH and IMPUTE. Although using pairwise-LD information
only, the weighted genotype scores in equations 2.2.11 and 2.2.12 provide an intuitive
justification of why incorporating external LD information may provide power gain for
12
association testing. In the following sections, we will consider both the pairwise LD-
based weighted genotype scores and multilocus LD-based imputation dosage scores
in the testing procedure.
2.2.3 Gene-based Interaction Analysis
Once we have calculated the scores, either weighted genotype scores in equation
2.2.11 and 2.2.12 or imputation dosage scores in MACH or IMPUTE, for each marker
in the reference data set, we can then test for gene-gene interaction based on the
scores (S
(j)
1 , . . . , S
(j)
Mj
) for gene j, where S
(j)
kj
= (S
(j)
1,kj
, . . . , S
(j)
n,kj
) and n is the total
number of individuals in the study. As the trait loci are unknown, a simple test
of interaction could be to include all pairwise interactions of the imputation dosage
scores in a regression framework and then test for their overall significance. However,
this approach may suffer from low power due to the large number of degrees of
freedom involved. To efficiently aggregate all information while reducing the degrees
of freedom, we propose to test for gene-gene interaction using PCs obtained from the
scores. Without loss of generality, for gene j, we order the PCs such that PC
(j)
1 has
the largest variance and PC
(j)
2 has the second largest variance and so on.
Once the PCs are computed, we can then test for gene-gene interaction by con-
ducting a regression analysis with a set of selected PCs and their interactions as
covariates. As the PCs are ordered by the magnitude of explained variance, for each
gene, we select the first several PCs that explain a prespecified fraction of the total
variance. Suppose Lj PCs are selected for gene j. For a binary trait, we can fit the
13
data with the following logistic regression model (see Supplementary Material)
logit[P (Y = 1|genotypes)] = α +
L1∑
l1=1
β1,l1PC1,l1
+
L2∑
l2=1
β2,l2PC2,l2
+
L1∑
l1=1
L2∑
l2=1
βl1,l2PC1,l1PC2,l2 .
(2.2.13)
For a quantitative trait, we can fit the data with a linear regression model.
Under the null hypothesis of no interaction between the two genes,H0 : βl1,l2 = 0 for
l1 = 1, . . . , L1 and l2 = 1, . . . , L2. We can test this null hypothesis by a likelihood
ratio test, and the corresponding test statistic is approximately distributed as a χ2
distribution with L1 × L2 degrees of freedom. We call this test as a global test.
Alternatively, we can conduct pairwise interaction analysis between all selected PCs
and choose the statistic for the most significant pair as the test statistic and evaluate
its significance by Bonferroni correction. We call this test as a pairwise test. In our
analyses, we used 90% threshold for the fraction of variance as it generally provides
better power than other variance thresholds in scenarios we considered. We note
that for binary traits, the null hypothesis tested by logistic regression is only an
approximation to the null hypothesis that (f2,2 − f2,0) − (f0,2 − f0,0) = 0, and thus
the weighted genotype scores we derived earlier may not be ’optimal’. However, as
shown in the Supplementary Material, this approximation is probably valid as long
as the interaction effects are not too strong and the disease is not common.
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2.3 Results
In this section, we evaluate the performance of the gene-based interaction tests for
binary traits and compare with SNP-based interaction test. We considered four gene-
based interaction tests: (1) ATOM-AVG, which uses weighted genotype scores from
equation 2.2.11; (2) ATOM-MAX, which uses weighted genotype scores from equation
2.2.12; (3) MACH, which uses imputation dosage scores from MACH; and (4) PCA,
which uses genotyped markers only. For each test T, we considered two versions: (1)
the global version, which tests for the joint interaction effect of all selected PCs; and
(2) the pairwise version, which tests for the pairwise interaction among all selected
PCs. Significance for the pairwise version is adjusted by Bonferroni correction. For
the SNP-based interaction analysis, we only considered the pairwise version as the
power of the global version is extremely low due to the large number of degrees of
freedom.
2.3.1 Comparison of Type I Error and Power
We simulated data based on the LD structures of two genes CHI3L2 (Figure 2.1)
and PTPN22 (Figure 2.2), both are located on chromosome 1 but are in linkage equi-
librium with each other. For each gene, we considered common SNPs with minor allele
frequency ≥ 0.05 and selected tagSNPs using the program Tagger (De et al. (2005))
with pairwise tagging at r2 ≥ 0.8. We identified 25 common SNPs for CHI3L2 and
selected seven tagSNPs; for PTPN22, 29 common SNPs and 9 tagSNPs. We assumed
that only the tagSNPs were genotyped and available for analysis, a common scenario
15
in both candidate gene and GWAS studies. To simulate case-control data with LD,
we first estimated the haplotype frequencies of the tagSNPs for each gene, and then
simulated the genotype data according to the estimated haplotype frequencies. We
considered two situations: (1) each gene has only one disease locus; and (2) each gene
has two disease loci.
For the first situation, we designated one locus in each gene as the disease locus,
and the case-control status for individual i was simulated according to the following
model
logit[P (Y = 1|g(1)i,D, g(2)i,D)] = α + 0.2(g(1)i,D + g(2)i,D) + 0.3g(1)i,Dg(2)i,D,
where α is determined in a way such that the overall disease prevalence is 5%. Power
was estimated based on 1000 replicate data sets each consisting of 2000 cases and
2000 controls and significance was assessed at the 1% level. The type I error rate was
evaluated based on 10000 data sets by setting the interaction effect in the above logit
model to 0. Since gene-based interaction tests based on ATOM and MACH require
external LD information, we simulated 60 individuals (mimicking the HapMap CEU
samples) as a reference data set and then calculated the weighted genotype scores
or the imputation dosage scores using the LD information estimated from these 60
individuals.
As the performance of different tests may vary depending on whether the disease
loci are genotyped or not, we considered three scenarios: 1) both disease loci are
genotyped; 2) only one of the disease loci is genotyped; and 3) both disease loci
are untyped. A thorough evaluation of all tests would require the consideration
16
of 25 × 29 = 725 combinations. To avoid extensive simulations from all marker
combinations, we classified the markers in each gene into three categories according
to LD levels. Specifically, a marker is classified into the ‘strong LD’ category if five
or more markers in the gene have r2 > 0.8 with it; a marker is in the ‘moderate LD’
category if three to five markers in the gene have r2 > 0.8 with it; the rest are in the
‘weak LD’ category. On the basis of this classification, markers in CHI3L fall into
either strong or weak LD categories. By classifying markers in this manner, we were
able to investigate the performance of various tests under a wide range of settings,
yet avoided simulations of all marker combinations.
Table 2.1 displays the estimated type I error rates under two-locus interaction
model. The type I error rates of all tests are under control. Not surprisingly, for
each test, the pairwise version of the test is more conservative than the global version
due to the correction of a large number of pairwise comparisons. Table 2.2 shows
the estimated power. As expected, when there is a single disease locus in each gene,
TSNP−pairwise consistently outperforms the other tests. Among the other tests we
considered, TATOM−AV G−global, TATOM−MAX−global and TMACH−global, which incorpo-
rate external LD information, offer better power, followed by TPCA−global.We note
that the powers of ATOM- and MACH-based tests are similar, despite that MACH
is much more computationally intensive. For example, it requires 210s to finish one
simulation for MACH-based tests with 2000 cases and 2000 controls; however, the
required computing time for ATOM-based tests is only 5s, 40 times faster.
For complex diseases, it might be an oversimplification to consider only one dis-
ease locus per gene. To evaluate the performance of different tests under a more
17
complicated setting, we considered a model in which two loci in CHI3L2 interact
with two loci in PTPN22. Specifically, we simulated case-control status according to
the model:
logit[P (Yi = 1|g(1)i,D1 , g
(1)
i,D2
, g
(2)
i,D1
, g
(2)
i,D2
)] = α + 0.3(g
(1)
i,D1
+ g
(1)
i,D2
+ g
(2)
i,D1
+ g
(2)
i,D2
)+
0.4(g
(1)
i,D1
g
(2)
i,D1
+ g
(1)
i,D1
g
(2)
i,D2
+ g
(1)
i,D2
g
(2)
i,D1
+ g
(1)
i,D2
g
(2)
i,D2
).
Again, the overall disease prevalence was set at 5% by adjusting the value of α. For
type I error estimation, we set the coefficient for the interaction effect at 0.
As shown in Table 2.3, the type I error rates of all interaction tests are under
control. Table 2.4 shows the power comparison results. These results indicate that
all gene-based interaction tests outperform the SNP-based test. For example, the
power advantage of TATOM−MAX−global over TSNP−pairwise as measured by mean power
difference ranged from 12.7 to 27.3%. This is much higher than the mean power
difference (4.1 − 9.7%) between the two tests under the simpler disease models in
Table 2.2. This indicates that SNP-based interaction analysis is not sufficient when
multiple loci in a gene interact with multiple loci in another gene. Among all gene-
based tests we considered, TMACH−global is generally the most powerful test, followed
by TATOM−MAX−global, TATOM−AV G−global and TPCA−global. It is worth noting that
the power of TATOM−MAX−global is only slightly lower than TMACH−global despite that
MACH is much more computationally intensive. The pairwise versions of these three
tests are typically less powerful than the global versions of the tests. Moreover, our
results clearly indicate the advantage of incorporating external LD information in the
analysis. The power gain of TATOM−MAX−global over TPCA−global as measured by the
18
mean power difference ranged from 3.3 to 7.9%, and the power gain of TMACH−global
over TPCA−global ranged from 4.6 to 10.7%.
2.3.2 Application to IBC HDL Data Set
We applied the three gene-based interaction tests to an ongoing candidate gene
study on subjects with extreme levels of HDL-C. In this study, 625 subjects of Euro-
pean ancestry with HDL > 90th percentile were considered as cases and 606 subjects
with HDL < 25th percentile were considered as controls. All study subjects were
genotyped using the IBC 50K SNP array (Keating et al. (2008)). Our previous SNP
pairwise interaction analysis on this data set reveals that a number of SNPs in CETP
significantly interact with several SNPs in BCAT1. It is well known that CETP
promotes the transfer of cholesteryl esters from HDL to low-density lipoprotein, and
individuals that are genetically deficient for CETP often have extremely high HDL
levels (Brown et al. (1989), Inazu et al. (1990)). In a recent GWAS on biochemical
traits, BCAT1 is shown to be significantly associated with serum albumin concentra-
tion (Zemunik et al. (2009)). As albumin is correlated with HDL (Gillum (1993)), it
is possible that CETP and BCAT1 interact in modulating the level of HDL-C.
Figure 2.3 and 2.4 display the LD structures of CETP and BCAT1 estimated
using the HDL data set. We downloaded genotype data at these two genes for the
CEU samples from the HapMap website. For CETP, there are 31 common SNPs in
the HapMap, whereas the HDL data set has 57, with 27 common SNPs in both data
sets. As the HapMap data set does not provide much additional LD information,
19
for ATOM-based tests, we calculated the weighted genotype scores using the LD
information provided by the 57 SNPs in the HDL controls. For BCAT1, 164 common
SNPs are in the HapMap and 79 are in the HDL data set, with 56 in both. For the
164 SNPs in the HapMap, we calculated their weighted genotype scores using the LD
information provided by the HapMap; for the 23 SNPs in the HDL data set but not
in the HapMap, we used their observed genotypes in the HDL data set.
The BCAT1 SNPs are in several LD blocks with weak LD between some of the
blocks, requiring 23 PCs to explain 90% of the variance. Testing interaction using all
SNPs in BCAT1 may have low power due to the large number of degrees of freedom.
To reduce the dimensionality, we divided the SNPs in BCAT1 into four blocks (Figure
2.4) and tested interaction between CETP and each of the four blocks. We found
significant interaction between CETP and the third block of BCAT1. The P-value
of TATOM−AV G−global is 0.0034. In comparison, the P-values of TATOM−MAX−global,
TMACH−global and TPCA−global are 0.22, 0.25 and 0.072, respectively. The P-values of
the pairwise versions of the four tests are 0.035, 0.062, 0.38 and 0.029, respectively.
The P-value of TSNP−pairwise is 0.078. Compared with other gene-based interaction
tests, TATOM−AV G−global clearly revealed stronger evidence of association.
2.4 Discussion
We have proposed a PC framework for gene-based interaction analysis. Our tests
are based on the aggregation of information from weighted genotype scores using
pairwise LD information or imputation dosage scores using multilocus LD informa-
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tion in a gene. To reduce dimensionality, the scores within a gene are further sum-
marized into PCs and then used in a regression framework for interaction analysis.
By extensive simulations under various settings and the analysis of a real data set,
we demonstrated that gene-based interaction tests are a powerful alternative to the
conventional SNP-based interaction test and to approaches that do not incorporate
external LD information.
The gene-based interaction tests consider each gene as a testing unit and tests for
interaction at the gene level. Compared with methods that operate at the marker
level, a key advantage of gene-based interaction tests lies in their ability to capture all
potential risk conferring variants in a gene. This makes gene-based interaction tests
particularly attractive when multiple disease loci in a gene interact with multiple
disease loci in another gene. We note that when a single locus in a gene interacts
with a single locus in another gene, or when some of the interaction effects are weak
when more than two loci interact, the SNP-based interaction test may perform well,
as such a simple test can capture the interaction effect more effectively than the
gene-based interaction tests.
Another advantage of gene-based interaction analysis over the conventional SNP-
based interaction analysis is that it requires much less number of tests. For example,
for the IBC data with 50000 SNPs genotyped in 2000 candidate genes, the conven-
tional SNP pairwise interaction analysis will involve 1.25 billion tests. In contrast,
using gene-based interaction analysis, the number of tests is reduced to 2 million. For
large-scale candidate gene and GWAS data sets, gene-based interaction tests can be
used as a screening tool. After a pair of significant interacting genes is identified,
21
one can then conduct further investigation to evaluate which SNPs within the genes
significantly interact.
Our method concerns with gene-based tests of interaction effect. We note that
there exist gene-based methods that jointly test for the main effect and the interaction
effect (Chatterjee et al. (2006); Chapman and Clayton (2007)). Although the goals
of these tests are slightly different from ours, they all aim to incorporate information
contributed by multiple markers in a gene. How to extend the proposed PC framework
to jointly test for the main and interaction effects would merit further research.
22
Figure 2.1: LD structure of the CHI3L2 gene on chromosome 1 in the HapMap CEU
samples. Displayed is estimated r2 for 25 SNPs with minor allele frequency (MAF)
≥ 0.05. SNPs within the black boxes are tagSNPs selected using the Tagger program
at r2 threshold of 0.8.
23
Figure 2.2: LD structure of the PTPN22 gene on chromosome 1 in the HapMap CEU
samples. Displayed is estimated r2 for 29 SNPs with MAF ≥ 0.05. SNPs within the
black boxes are tagSNPs selected using the Tagger program at r2 threshold of 0.8.
Figure 2.3: LD structure of the CETP gene on chromosome 16 in the IBC samples.
24
Figure 2.4: LD structure of the BCAT1 gene on chromosome 12 in the IBC samples.
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2.5 Supplementary Material
Derivation of ATOM Weighted Genotype Scores for Binary Trait
We now consider gene-based interaction analysis for binary traits, such as disease
status. Assuming there is no interaction on the penetrance scale, i.e., the two-locus
penetrance fgD1 ,gD2 = P (Y = 1|gD1 , gD2) can be written as the sum of the disease
risks due to each disease locus. Here gDj ∈ {0, 1, 2} is the number of disease allele Dj
at disease locus j(= 1, 2). It is easy to show that this definition of no interaction is
equivalent to (f2,2 − f2,0)− (f0,2 − f0,0) = 0. Suppose marker j is in LD with disease
locus j. Let ϕg1,g2 = P (Y = 1|g1, g2) denote the penetrance for genotypes (g1, g2) at
markers 1 and 2. Then
ϕg1,g2 = P (Y = 1|g1, g2) =
∑
gD1
∑
gD2
P (Y = 1, gD1 , gD2 |g1, g2)
=
∑
gD1
∑
gD2
fgD1 ,gD2P (gD1|g1)P (gD2|g2).
For gene j, the conditional probability P (gDj |gj) depends on the LD between the
marker j and disease locus j. Let 4j = pDjAj − pDjpAj = −pdjAj + pdjpAj be the
LD coefficient between them. Assume both disease loci follow an additive model.
Let K0 = f0,0p
2
d1
+ 2f1,0pd1pD1 + f2,0p
2
D1
, K1 = f0,1p
2
d1
+ 2f1,1pd1pD1 + f2,1p
2
D1
and
K2 = f0,2p
2
d1
+ 2f1,2pd1pD1 + f2,2p
2
D1
. It can be shown that
ϕ0,0 =
p2a2d2
p2a2
{K0 − 1
pa1
[241(f1,0 − f0,0)]}+ 2pa2d2pa2D2
p2a2
{K1 − 1
pa1
[241(f1,1 − f0,1)]}
+
p2a2D2
p2a2
{K2 − 1
pa1
[241(f1,2 − f0,2)]}.
Similarly,
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ϕ0,2 =
p2A2d2
p2A2
{K0 − 1
pa1
[241(f1,0 − f0,0)]}+ 2pd2pA2D2
p2A2
{K1 − 1
pa1
[241(f1,1 − f0,1)]}
+
p2A2D2
p2A2
{K2 − 1
pa1
[241(f1,2 − f0,2)]}
ϕ2,0 =
p2a2d2
p2a2
{K0 + 1
pA1
[241(f1,0 − f0,0)]}+ 2pa2d2pa2D2
p2a2
{K1 + 1
pA1
[241(f1,1 − f0,1)]}
+
p2a2D2
p2a2
{K2 + 1
pA1
[241(f1,2 − f0,2)]}
ϕ2,2 =
p2A2d2
p2A2
{K0 + 1
pA1
[241(f1,0 − f0,0)]}+ 2pA2d2pA2D2
p2A2
{K1 + 1
pA1
[241(f1,1 − f0,1)]}
+
p2A2D2
p2A2
{K2 + 1
pA1
[241(f1,2 − f0,2)]}.
Under additive model, we have 2(f1,i − f0,i) = f2,i − f0,i for j = 0, 1, and 2. Since
42 = pD2A2 − pD2pA2 = pd2a2 − pd2pa2 = −pd2A2 + pd2pA2 = −pD2a2 + pD2pa2 , thus the
relationship between the penetrance of genotyped markers can be simplified as
(ϕ2,2 − ϕ2,0)− (ϕ0,2 − ϕ0,0) = 241(f1,0 − f0,0)
pA1pa1
(
p2A2d2
p2A2
− p
2
a2d2
p2a2
)
+
241(f1,1 − f0,1)
pA1pa1
(
2pA2d2pA2D2
p2A2
− 2pa2d2pa2D2
p2a2
)
+
241(f1,2 − f0,2)
pA1pa1
(
p2A2D2
p2A2
− p
2
a2D2
p2a2
)
=
41(f2,0 − f0,0)
pA1pa1
42
pA2pa2
[
42
pA2pa2
(pa2 − pA2)− 2pd2 ]
+
41(f2,1 − f0,1)
pA1pa1
42
pA2pa2
[
42
pA2pa2
(pA2 − pa2) + pd2 − pD2 ]
+
41(f2,2 − f0,2)
pA1pa1
42
pA2pa2
[
42
pA2pa2
(pa2 − pA2) + 2pD2 ]
=
41
pA1pa1
42
pA2pa2
[(f2,2 − f2,0)− (f0,2 − f0,0)].
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Similarly to what we have shown for quantitative traits, the interaction effect between
the markers also relates to the interaction effect between the disease loci, with the
same multiplying factor [ 41
pA1pa1
][ 42
pA2pa2
]. This suggests that the weighting scheme
as defined previously for quantitative traits can also be used for binary traits to
appropriately aggregate information from all markers within each gene.
Test of Interaction for Binary Trait
Our goal is to test the null hypothesis (f2,2−f2,0)−(f0,2−f0,0) = 0, i.e.,f2,2−f0,0 =
(f2,0 − f0,0)− (f0,2 − f0,0). However, this null hypothesis cannot be directly tested in
case-control studies because the risks (i.e., penetrances) are not directly estimable.
Hence, approximations are required to test for interaction. Let r denote the genotype
relative risk, then the null hypothesis of no interaction can be rewritten as r2,2− 1 =
(r2,0−1)− (r0,2−1). If all the relative risks are near one, then r2,2−1 ≈ 0. Since x ≈
log(1+x) for x ≈ 0, thus the null hypothesis of no interaction can be approximated by
log(r2,2) = log(r2,0) + log(r0,2). If, in addition, all the penetrances are near zero (e.g.
rare diseases), then 1−fi,j ≈ 1, and the genotype relative risks can be approximated by
odds ratios, ri,j = fi,j/fi,j ≈ [fi,j/(1−f0,0)]/[f0,0/(1−f0,0)] = ORi,j. In this situation,
the null hypothesis of no interaction can be further approximated by log(OR2,2) =
log(OR2,0) + log(OR0,2) (i.e. additivity on the log odds scale), which suggests that
interaction can be tested by logistic regression. The above derivations indicate that
the weighted genotype scores we derived earlier may not be ”optimal” when used in
logistic regression since it is based on a two-step approximation. However, when the
genotype relative risks are near one and the penetrances are near zero, these scores
may still perform well.
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Chapter 3
A Gaussian Copula Approach for
the Analysis of Secondary
Phenotypes in Case-Control
Genetic Association Studies
33
3.1 Introduction
Genome-wide association studies (GWAS) offer a powerful tool to identify genes
that confer moderate disease risks. In these studies, the main outcome of interest
is often disease status. However, in many of these studies, a set of correlated sec-
ondary phenotypes that may share the same genetic factors with disease status are
also collected. Examination of these secondary phenotypes may provide important
clues about the disease etiology and supplement the main studies. Various secondary
phenotypes have been suggested as useful for gene mapping of complex diseases. For
example, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) levels for coronary artery disease (Grundy et al. (2004)), and
angiotensin-converting enzyme activity for hypertension (Kammerer et al. (2004))
are clear examples of useful secondary phenotypes. In some situations, the analysis
of secondary phenotypes may become the primary focus of subsequent studies. Re-
cently, there have been several GWAS on secondary phenotypes, such as BMI and
lipid levels (Kathiresan et al. (2008); Loos et al. (2008); Teslovich et al. (2010); Willer
et al. (2008)), where most of the data came from case-control studies of complex dis-
eases, such as diabetes, hypertension, and heart disease.
Commonly used approaches for the analysis of secondary phenotypes rely on stan-
dard regression that assesses the effect of SNPs using controls only, cases only, com-
bined data of cases and controls, or joint analysis of cases and controls adjusting for
disease status. However, none of these methods are statistically correct and may lead
to false positive associations (Lin and Zeng (2009)). The reason is that in a study
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where the samples are ascertained according to disease status, cases and controls no
longer constitute a random sample of the general population. As a result, the popu-
lation association between a marker and a secondary phenotype can be distorted in
the case-control data.
Several methods have been developed to correct for the sampling bias in the anal-
ysis of secondary phenotypes. Monsees et al. (2009) proposed an inverse-probability-
of-sampling weighted regression approach to incorporate selection probability in like-
lihood calculation. Lin and Zeng (2009) proposed a retrospective likelihood approach
that conditions on disease status. Although these methods are useful, they make
restrictive assumptions on the distribution of the secondary phenotypes. It is thus
desirable to develop methods that allow the modeling of secondary phenotypes that
do not fit the above-mentioned methods distributional assumptions. Since the pri-
mary and secondary phenotypes are often correlated, a critical first step in devising
such methods is on modeling the joint distribution of the primary and secondary
phenotypes.
In statistics, copulas are used as a general way of formulating multivariate distri-
butions (Nelsen (1999)). The rationale is that a simple transformation can be made
for each marginal variable in a way such that each transformed marginal variable has
a uniform distribution. Once the transformation is done, the dependence structure
can then be expressed as a multivariate distribution on the obtained uniforms, and
a copula is precisely a multivariate distribution on marginally uniform random vari-
ables. A commonly used copula is the Gaussian copula, which is constructed from
multivariate normal distribution via Sklar’s theorem. Gaussian copulas share many
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similarities with the multivariate normal distribution, and are useful for constructing
joint distributions of continuous, discrete, or mixed types of outcomes (Song et al.
(2009); De Leon and Wu (2011)).
Gaussian copulas have been previously employed in linkage studies for mapping
quantitative trait loci (Li et al. (2006)). Here we extend the analysis to association
mapping in which we use Gaussian copulas to model the joint distribution of the
disease status variable and secondary phenotypes. An advantage of our method is
that it can handle a variety of secondary phenotypes as long as the distribution comes
from an exponential family, making it much more flexible than existing methods.
We show through extensive simulations that our method yields correct type I error
rates even when the model is mis-specified. We also demonstrate the effectiveness
of our method in the analysis of a genome-wide association study on high HDL-C in
which LDL-C and three apolipoprotein levels including ApoA1, ApoB and ApoC3
are treated as secondary phenotypes.
3.2 Methods
3.2.1 Gaussian Copula and Joint Analysis of Correlated Mixed
Outcomes
The central idea of our method is to jointly model the distribution of disease
status and secondary phenotypes using Gaussian copulas. This is based on the
likelihood framework that we previously developed for joint regression analysis of
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correlated mixed outcomes (Li et al. (2006); Song et al. (2009)). Below we briefly
review results from our previous work. Consider m dependent random variables
y1, . . . , ym. Let Fj(yj) denote the cumulative distribution function (CDF) of yj,
which is assumed to be from an exponential family. The density function of yj is
f(yj; ηj, ϕj) = exp{(yjηj− b(ηj))/a(ϕj) + c(yj, ϕj)}, where a, b and c are known func-
tions, ϕj is the dispersion parameter, and ηj is the canonical parameter. The mean
and variance of yj are given by E(yj) = µj = b
′
(ηj) and var(yj) = b
′′
(ηj)a(ϕj) ,
respectively. Since the CDF is uniformly distributed on the [0, 1] interval, the joint
distribution function of y1, . . . , ym can be modeled through a Gaussian copula, defined
as Φm(Φ
−1(F1(y1)), . . . ,Φ−1(Fm(ym))|Γ), where Φ and Φm are the standard univariate
and multivariate normal distribution functions, and Γ is an m×m correlation matrix.
With Gaussian copulas, the handling of a multivariate distribution can be separated
into a marginal model for the inverse normal score Φ−1(Fj(yj)) and a model for the
joint distribution of the inverse normal scores.
In our previous work (Li et al. (2006)), we showed that when the first m1 of the
outcome variables are discrete and the remaining outcome variables are continuous,
the joint density of y1, . . . , ym is
P (y1, . . . , ym) =
m∏
j=m1+1
fj(yj; ηj, ϕj)
2∑
j1
. . .
2∑
jm1=1
(−1)j1+...+jm(2pi)−m12 |Γ|− 12
∫ Φ−1(µ1,j1 ))
−∞
. . .
∫ Φ−1(µm1,jm1 ))
−∞
exp[−1
2
(y, q)Γ−1(yT , qT ) +
1
2
qqT ]dy,
(3.2.1)
where y = (y1, . . . , ym), q = (Φ
−1(Fm1+1(ym1+1)), . . . ,Φ
−1(Fm(ym))), µj,1 = F (yj−; ηj, ϕj)
and µj,2 = Fj(yj; ηj, ϕj). Here F (yj−; ηj, ϕj) is the left-hand limit of Fj at yj, which is
equal to F (yj−1; ηj, ϕj) when yj takes integer values as for the Poisson and Binomial
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distributions.
The above likelihood allows us to model the joint distribution between disease
status and those continuous secondary phenotypes. Let y1(1=affected; 0=unaffected)
denote the disease status, and y2, . . . , ym denote those secondary phenotypes. Based
on the likelihood given in equation 3.2.1, we can show that the joint density function
of y1, . . . , ym is
P (y1, . . . , ym) =
m∏
j=2
f(yj; ηj, ϕj)
[1−
∫ Φ−1(1−µ1)
−∞
1√
2pi|Γ|exp{−
1
2
(z, q)Γ−1(z, q)T +
1
2
qqT}dz]I(y1=0)
[
∫ Φ−1(1−µ1)
−∞
1√
2pi|Γ|exp{−
1
2
(z, q)Γ−1(z, q)T +
1
2
qqT}dz]I(y1=1),
(3.2.2)
where I{·} is an indicator function. In particular, if there is only a single secondary
phenotype and it is normally distributed, then the joint density function of y1 and y2
can be simplified as
P (y1, y2) = φ(y2;µ2, σ2)[1− Φ(Φ
−1(µ1) + γ(y2 − µ2)/σ2√
1− γ2 )]
I(y1=0)
Φ(
Φ−1(µ1) + γ(y2 − µ2)/σ2√
1− γ2 )
I(y1=1),
(3.2.3)
where φ is the density of a normal random variable, σ2 is the standard deviation of
y2, and γ is the correlation parameter that characterizes the degree of correlation
between y1 and y2 with |γ| 6= 1. Obviously, when γ = 0, the cases and controls
share the same density for the secondary phenotype; when γ 6= 0, the distributions
are different with both mean shift and rescaling, and this makes the copula approach
flexible in capturing the shape of real data. From equation 3.2.3, we can easily derive
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the conditional probability of y1 given y2
P (y1 = 1|y2) = Φ(Φ
−1(µ1) + γ(y2 − µ2)/σ2√
1− γ2 ), (3.2.4)
which suggests that when γ > 0, the probability of being affected increases with y2.
3.2.2 Retrospective Likelihood for Secondary Phenotype
In a case-control study, since the data are ascertained based on disease status, y1,
to reflect the sampling scheme and to make valid inference on the secondary pheno-
types, a retrospective likelihood would be appropriate (Kraft and Thomas (2000)).
Let g(= 0, 1, 2) denote the genotype (counting the number of minor alleles) at the
test SNP for an individual. Then the retrospective likelihood of the individual is
P (y2, . . . , ym, g|y1) = P (y1, . . . , ym|g)P (g)
P (y1)
=
P (y1, . . . , ym|g)P (g)∑2
g=0 P (y1|g)P (g)
, (3.2.5)
where P (g) is the genotype frequency at the test SNP. Assume Hardy-Weinberg
equilibrium, then the genotype frequencies can be calculated as P (g = 0) = (1 −
p)2, P (g = 1) = 2p(1 − p), and P (g = 2) = p2, where p is the minor allele frequency
(MAF) of the test SNP. We can relate g with the marginal mean model for each
of the phenotypes through the use of a link function h(µj) = β0,j + β1,j × g. The
specification of the link function depends on the distribution of the phenotype. For
the disease status variable, we can model its marginal mean by the logit link function
log[µ1/(1 − µ1)] = β1,0 + β1,1 × g, where µ1 = P (y1 = 1|g). For the j-th secondary
phenotype, h(µj) = βj,0 +βj,1×g, the marginal mean model will be determined by its
distribution; for example, for a normally distributed random variable, h(µj) = µj; for
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a Poisson distributed random variable, h(µj) = log(µj); for a binary random variable,
h(µj) = log[µj/(1−µj)]; for a gamma distributed random variable, one can use either
a reciprocal link function h(µj) = 1/µj or a log link function h(µj) = log(µj). For
a case-control study with a total of n subjects, the overall likelihood is simply the
product of the likelihoods across all individuals.
After the likelihood is specified, the next step is to establish simultaneous maxi-
mum likelihood inference for all parameters θ = ({βj,0, βj,1, γj}mj=1, p), where γj is the
parameter that characterizes the correlation between y1 and yj (note that γ1 = 1
by definition). When the data only contain unrelated cases and controls, these
parameters are not all identifiable. In our analysis, we fixed the disease preva-
lence and updated the intercept parameter for the primary phenotype by β1,0 =
β∗1,0 + log[K/(1−K)], where β∗1,0 is the intercept estimate obtained from a logistic re-
gression on the disease status variable with the SNP genotype included as a covariate.
By using this strategy, we avoided estimating the intercept parameter β1,0.
Let l(θ) denote the log-likelihood function. To find the maximum likelihood esti-
mate (MLE) θˆ = argmaxθl(θ) numerically, we implement a Gauss-Newton type algo-
rithm (Ruppert (2005)), which only requires the first derivatives of the log-likelihood
function. We search for the MLE by taking step-halving to guarantee that the like-
lihood increases progressively over iterations. Specifically, the (k + 1)-th iteration
updates the parameter θ by
θk+1 = θk + ε{Bn(θk)}−1∂l(θ
k)
∂θ
, (3.2.6)
where Bn =
∑n
i=1(
∂l(θ)
∂θ
)(∂l(θ)
∂θ
)T and ε is the step-halving term that starts at 1 and
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halves until l(θk+1) > l(θk) at iteration k. The algorithm stops when the increase
in the likelihood is no longer possible or the difference between the two consecutive
update is smaller than a prespecified precision level. To determine the initial values
in the optimization, we conduct univariate analysis for the primary and secondary
phenotypes and use parameter estimates obtained from these analyses as initial val-
ues. For the correlation parameter, we estimate the Pearson correlation between the
primary and secondary phenotypes and use that as the initial value. The variances
of the parameters are approximated by numerical Fisher information. This Gauss-
Newton type algorithm works well for Gaussian copulas and it generally converges in
less than 10 iterations.
With the previously developed likelihood framework, we can evaluate whether the
test SNP is associated with the j-th secondary phenotype using a Wald test WS =
ˆβj,1
2
/ ˆvar(βj,1). Under the null hypothesis of no association, WS is asymptotically
distributed as a chi-squared distribution with one degree of freedom.
3.3 Simulation Studies
3.3.1 Simulation Setup
We conducted extensive simulations to examine the performance of the copula-
based approach and to compare it with several existing methods. We considered a
SNP with MAF of 0.3 and a single secondary phenotype that is normally distributed.
To generate correlated disease status and secondary phenotype, we first simulated y2
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from a normal distribution N(µ2, 1), where µ2 = β2,0 + β2,1 × g. We then simulated
y1 from the conditional distribution of y1|y2 based on equation 3.2.4. An individual’s
disease status was determined by comparing a randomly generated number with the
pre-specified penetrance function P (y1 = 1|g) = µ1 = exp(β1,0 + β1,1 × g)/[1 +
exp(β1,0 + β1,1 × g)]. The value of β1,0 was determined such that the overall disease
prevalence is 5%, and the value of β1,1 was determined by the odds ratio OR =
exp(β1,1). For the secondary phenotype, we set β2,0 = 0, and the value of β2,1 was
determined by heritability h2 = 2β22,1p(1−p)/[1+2β22,1p(1−p)], i.e., the proportion of
phenotypic variation explained by the test SNP. After a large pool of individuals was
simulated, we then sampled 1,000 cases and 1,000 controls from the pool. We analyzed
the secondary phenotype in each simulated dataset using the following methods: 1)
the copula-based approach, 2) linear regression with cases only, 3) linear regression
with controls only, 4) linear regression with cases and controls combined without
adjustment of disease status, 5) linear regression with cases and controls combined
with adjustment of disease status, and 6) Lin and Zeng’s method (Lin and Zeng
(2009)). Type I error rates were estimated based on 100,000 simulations, and power
was estimated based on 10,000 simulations.
3.3.2 Analysis of Secondary Phenotype
Empirical Type I Error Rates
The upper part of Table 3.1 shows the empirical type I error rates of different
methods for the analysis of the secondary phenotype when the test SNP is not asso-
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ciated with the disease. As expected, the type I error rates of all methods are close
to the 1% nominal level. We next evaluated the performance of different methods
when the test SNP is associated with the disease at OR = 1.2. As shown in the lower
part of Table 3.1, only the copula-based approach and the control-only analysis have
controlled type I error rates. In contrast, the type I error rates of the other methods
are inflated when the disease status and secondary phenotype are correlated, and the
degree of inflation increases with the degree of correlation. Of note, Lin and Zeng’s
method is a parametric based method. It is not surprising that its type I error rate
is slightly inflated as the simulated data do not fit their distributional assumption.
Empirical Power
As shown in the upper part of Figure 3.1, when the test SNP is not associated with
the disease, the copula-based approach, Lin and Zeng’s approach, and the case-control
combined analysis adjusting disease status have comparable power and outperform
the other methods. The analysis using both cases and controls without adjustment
of disease status has comparable power with the above-mentioned three methods at
low correlation but becomes less powerful when the degree of correlation increases.
Not surprisingly, case-only and control-only analyses have less power than analysis
methods that include the entire sample.
When the test SNP is associated with the disease, we excluded the case-only,
and case-control combined unadjusted analyses from power comparison due to their
serious inflation of type I error rates. Not surprisingly, methods that use the en-
tire sample, such as the copula-based approach, Lin and Zeng’s approach, and the
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combined analysis adjusting disease status, are more powerful than the control-only
analysis (lower part of Figure 3.1). The power of Lin and Zeng’s analysis and the
combined-adjusted analysis are similar and both decrease as the correlation increases
in the positive direction. We note that the type I error rates of these two tests are
slightly inflated when |γ| > 0.3, and thus their power should be interpreted with
caution.
Evaluation of Robustness of the Copula-based Approach
Results in the previous sections were obtained based on data simulated from the
copula model. To evaluate the robustness of our method, we simulated data from a
model employed by Lin and Zeng (2009). In this model, the secondary phenotype
was assumed to be normally distributed with mean µ2 = α2,0 + α2,1 × g and stan-
dard deviation 1, and the disease status was simulated according to a logit model
log[µ1/(1− µ1)] = α1,0 + α1,1 × g + α1,2 × y2. In this model, the correlation between
the disease status and secondary phenotype is introduced through α1,2 in the logit
function.
Table 3.2 shows the estimated type I error rates of the copula-based approach
and Lin and Zeng’s approach. As indicated by its controlled type I error rates, the
copula-based approach is robust to misspecification of the models. We also compared
the power of the copula-based approach and Lin and Zeng’s approach. As shown
in Figure 3.2, these two methods have comparable power when the test SNP is not
associated with the disease; when the test SNP is associated with the disease, the
copula-based approach is more powerful than Lin and Zeng when the disease status
44
variable and the secondary phenotype are positively correlated, but Lin and Zeng’s
approach is more powerful when the correlation is negative.
3.4 Application to a Genetic Association Study on
High HDL
The University of Pennsylvania High HDL Cholesterol Study is a cross-sectional
study of genetic factors contributing to elevated HDL-C levels and is composed of
subjects with extreme levels of HDL-C. In this study, subjects of European ancestry
with HDL > 90th percentile for age and gender were considered as cases and sub-
jects with HDL < 30th percentile for age and gender were considered as controls.
605 cases and 724 controls were genotyped using Affymetrix 6.0 SNP array. The
primary phenotype is the HDL-C case-control status. In addition, all study subjects
have measurements on LDL-C and chemical measures of apolipoprotein A1 (ApoA1),
apolipoprotein B (ApoB) and apolipoprotein C3 (ApoC3) protein concentration.
Our GWAS analysis revealed strong association between HDL case-control status
and a number of SNPs in LIPG, a gene located on chromosome 18. It is well-known
that LIPG plays an important role in the regulation of HDL-C level. In a recent meta-
analysis of 46 GWAS of lipids in >100,000 individuals (Teslovich et al. (2010)), LIPG
was found to be strongly associated with HDL-C (rs7241918: P-value = 3 × 10−49).
However, this study did not find evidence of association between LIPG and LDL-C.
In another GWAS of plasma lipoprotein size, concentration, and cholesterol content
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in >17,000 individuals (Chaseman et al. (2009)), LIPG was found to be significantly
associated with ApoA1 (rs4939883: P-value = 5.60×10−14) but not with ApoB. Since
ApoC3 was not included in this study, it is unclear what the role is for LIPG in the
regulation of ApoC3 levels.
In our analysis, we treated LDL-C, ApoA1, ApoB and ApoC3 levels as secondary
phenotypes. We analyzed each of them separately with the HDL case-control status.
The purpose is to investigate whether SNPs in LIPG are associated with these sec-
ondary phenotypes. For each of the 85 SNPs in LIPG, we tested association with the
secondary phenotype using 1) the copula-based approach, 2) Lin and Zeng’s approach,
3) case-control combined analysis adjusting case-control status, and 4) case-control
combined unadjusted analysis. For the copula-based approach, we standardized each
secondary phenotype by subtracting its mean estimated from controls and then di-
vided by its standard deviation estimated using all samples. Figure 3.3 displays the
P -values for the analysis of secondary phenotypes together with the P -values for the
analysis of the HDL-C case-control status.
For ApoB, whose level is weakly correlated with HDL-C case-control status (γ =
−0.06), the four methods have comparable P -values for all tested SNPs. For LDL-C,
which shows moderate correlation with HDL-C (γ= 0.16), the P -values from the case-
control combined unadjusted analysis are more significant than the other methods
for most SNPs in LIPG. Since LIPG is not associated with LDL-C (Chaseman et al.
(2009); Teslovich et al. (2010)), the significant results from the case-control combined
unadjusted analysis are likely due to false positive associations.
For ApoC3, which is more strongly correlated with HDL-C (γ = 0.20), the results
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from the case-control combined unadjusted analysis become even more significant
than approaches that aim to correct for ascertainment bias. For example, for the three
SNPs (rs10438978, rs2156552, and rs4939883) that are significantly associated with
HDL-C case-control status (P -value < 0.001), they all show significant association
with ApoC3 (P -value < 0.005) using the case-control combined unadjusted analysis;
however, the corresponding P -values by the other three approaches are all greater
than 0.01. In particular, the copula-based approach yielded the least significant results
with the P -values greater than 0.05 for two of the three SNPs (rs2156552: P -value
= 0.0521; rs4939883: P -value = 0.0502). Although the role of LIPG on ApoC3
level is still unclear, based on our simulations (Table 3.1), we found that when the
correlation between the primary and secondary phenotypes is 0.2 and the OR for
the primary phenotype is 1.2, the type I error rate for the case-control combined
unadjusted analysis can be as high as 2% (at the 1% significance level). Since the
ORs for the above-mentioned three LIPG SNPs are >1.4, the degree of type I error
inflation for the case-control combined unadjusted analysis might be even higher than
2%. This suggests that the small P -values from the case-control combined unadjusted
analysis for ApoC3 are possibly due to false positive signals.
For ApoA1, which is strongly correlated with HDL-C (γ = 0.80), the copula-based
method revealed evidence of association at rs4939883 (P -value = 0.0073), the same
SNP reported by (Chaseman et al. (2009)). The corresponding P -value from the case-
control combined unadjusted analysis is slightly more significant (P -value = 0.0059).
This reduced P -value is possibly due to the ignorance of ascertainment bias in the
analysis. On the other hand, the case-control combined adjusted analysis yielded a
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P -value of 0.099 at rs4939883. Of note, Lin and Zeng’s method failed to converge
for all SNPs due to high correlation between ApoA1 and HDL-C. Our results for
the analysis of ApoA1 suggest that the copula-based method not only prevents false
positive associations, but also does not remove true associations.
3.5 Discussion
We have developed a Gaussian copula-based approach for the analysis of secondary
phenotypes collected from case-control genetic association studies. Through extensive
simulations, we showed that our method has controlled type I error rates even when
the model was mis-specified. We also demonstrated the effectiveness of our method
in the analysis of a real dataset and showed that inappropriate analysis of secondary
phenotypes may lead to false positive association signals and produce misleading
results.
Compared with existing methods, our method has several advantages. First, it is
flexible and can handle a variety of secondary phenotypes as long as the trait distri-
bution comes from an exponential family. Second, it is able to incorporate multiple
correlated secondary phenotypes, whereas the existing methods such as Monsees et
al. (2009) and Lin and Zeng (2009) can only handle a single secondary phenotype.
Although we only showed results for the analysis of a single secondary phenotype,
we also conducted simulations with two secondary phenotypes, and found that the
copula-based approach still maintains controlled type I error rates, and moreover, it
offers even more power gain over univariate analysis (data not shown). Third, our
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method can analyze secondary phenotypes that have different marginal distributions.
This feature is particularly appealing for practical analysis. For example, we are
currently working on a GWAS on coronary artery disease (CAD). In this study, the
primary outcome of interest is CAD status. However, in addition to CAD status,
we also have information on many secondary phenotypes that are closely related to
CAD, including lipid levels such as HDL-C, LDL-C, triglyceride, and coronary artery
calcium score. These traits are all correlated with CAD, but have different marginal
distributions. Flexible methods such as the copula-based approach are critical for
proper analysis of such type of data.
In this paper, we focused on the analysis of the secondary phenotypes. However,
our likelihood framework is general and also allows us to test for association with the
primary phenotype, i.e., the disease status. Our preliminary results indicate that by
incorporating secondary phenotypes that are moderately correlated with the disease
status (e.g. correlation γ > 0.3), there can be noticeable power improvement over the
standard logistic regression that only considers the disease status.
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Table 3.1: Comparison of type I error rates (%) for the analysis of secondary pheno-
type. Significance was assessed at 1% significance level based on 100,000 simulations.
γ is the correlation parameter between the primary and secondary phenotypes.
Case-control Case-control
Lin- Case- Control- combined combined
γ Copula Zeng only only unadjusted adjusted
h2 = 0, OR = 1.0
-0.4 1.00 1.01 1.03 1.02 0.90 0.98
-0.3 1.04 1.01 0.99 1.00 1.01 1.00
-0.2 0.93 0.99 1.03 1.06 0.99 0.97
-0.1 0.97 1.01 1.02 0.95 1.00 1.00
0 1.00 1.04 1.04 1.01 1.02 1.03
0.1 1.00 1.00 0.96 1.02 0.98 0.98
0.2 1.00 1.09 1.06 0.97 1.05 1.08
0.3 0.96 1.03 0.95 1.04 1.03 1.00
0.4 0.98 1.08 0.98 1.02 1.02 1.05
h2 = 0, OR = 1.2
-0.4 1.05 1.38 2.31 0.97 5.05 1.68
-0.3 1.06 1.20 1.57 0.98 3.44 1.31
-0.2 1.07 1.14 1.23 0.93 2.00 1.16
-0.1 0.95 1.02 1.09 0.97 1.26 1.01
0 1.00 0.97 1.00 1.01 0.97 0.96
0.1 0.99 1.09 1.06 0.99 1.24 1.08
0.2 0.98 1.09 1.21 1.06 1.99 1.12
0.3 1.02 1.23 1.65 0.97 3.13 1.35
0.4 1.09 1.29 2.35 0.98 5.69 1.73
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Table 3.2: Comparison of type I error rates (%) for the analysis of secondary pheno-
type when data were simulated from Lin and Zeng’s model. Significance was assessed
at 1% significance level based on 100,000 simulations. α1,2 is a parameter that deter-
mines the correlation between the primary and secondary phenotypes.
OR = 1.0 OR = 1.2
α1,2 Copula Lin-Zeng Copula Lin-Zeng
-0.4 0.97 1.05 1.04 1.04
-0.3 1.01 1.05 1.05 1.01
-0.2 1.01 1.00 1.03 1.02
-0.1 0.99 0.96 1.00 1.05
0 0.94 0.96 0.99 1.00
0.1 0.96 1.02 0.98 1.00
0.2 0.99 1.05 0.97 1.05
0.3 0.96 1.00 1.00 1.00
0.4 0.98 1.02 1.03 0.94
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Figure 3.1: Comparison of power for the analysis of secondary phenotype. Significance
was assessed at 1% significance level based on 10,000 simulations.
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Figure 3.2: Comparison of power when data were simulated from Lin and Zeng’s
model. Significance was assessed at 1% significance level based on 10,000 simulations.
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Figure 3.3: Association results from four different procedures for the analysis of LDL-
C, ApoB, ApoC3, and ApoA1 levels in the high HDL study. HDL-C association was
evaluated by logistic regression. The grey line corresponds to P -value = 0.05.
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Chapter 4
Penalized Estimation of Gaussian
Copula Model for Secondary
Phenotype Analysis
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4.1 Introduction
In genome-wide association studies, a set of correlated phenotypes other than the
phenotype that defines the disease status are often collected. These phenotypes are
often called the secondary phenotypes. Given the already genotyped data and avail-
able phenotypes, it is of interest to identify markers associated with the secondary
phenotypes. Examination of the secondary phenotypes can yield valuable insights
about disease etiology and supplement the main study. Given the large number of
SNPs, the signals from single marker association may no longer be significant when
adjusted for multiple testing. Instead of single marker tests, an alternative is to per-
form variable selection in order to identify the disease-associated genetic variants.
However, direct application of the commonly used variable selection methods devel-
oped for linear regression models such as Lasso (Tibshirani (1996)) for analysis of the
secondary phenotypes are statistically incorrect because cases and controls are col-
lected at different rates from their subpopulations, thus case control sample does not
constitute a random sample of the general population. To correct for the sampling
bias we propose to develop variable selection method in a Gaussian copula modeling
framework that effectively utilizes the information provided by the disease status.
The Gaussian copula model can effectively model the joint distribution of two or
more random variable where only the marginal distributions of the variables need to
be specified. Such models can effectively model the between-outcomes association
and provide unbiased marginal parameter estimates when the association parameter
is correctly modeled.
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In this paper, we propose to develop a penalized likelihood approach based on
the Gaussian copula model for selecting the relevant markers that are associated
with the secondary phenotypes. Our procedure involves two steps: first we employ
variable selection methods such as Lasso or sure independence screening (Fan and
Song (2010)) to select the markers that are associated with the primary outcome.
This can be done unbiased by fitting logistic or penalized logistic regression models.
We then treat these markers as known and in the second step, we propose to develop
a penalized likelihood approach to select the markers that are associated with the
secondary outcomes. We develop an efficient gradient descent algorithm to perform
the optimization. We choose the tuning parameters using the BIC or extended BIC
(eBIC) that was developed for high dimensional regressions (Chen (2008)).
This paper is organized as follows. We first introduce the Gaussian copula model
for joint modeling of primary and secondary outcomes and for analysis of multiple
markers. We then present a penalized likelihood approach for variable selection.
An efficient computational algorithm based on the coordinate gradient descent is
then presented to solve the optimization problem. We perform simulation studies to
evaluate our method and compare the results with the Lasso and adjusted Lasso that
includes the case control status in the regression model. Finally, we apply the method
to a genetic association study on HDL.
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4.2 Statistical Methods
4.2.1 Gaussian Copula Model for Correlated Phenotypes
For simplicity, we consider the setup where we have a binary primary outcome such
as the case-control status and a continuous secondary phenotype. Let Y1 denote the
disease status that takes value of 0 and 1, and let Y2 denote the secondary continuous
phenotype. Let g = (g1, ..., gp) be the set of p SNP markers that we consider. Suppose
there are n i.i.d. samples and let (y1i, y2i)i=1,...,n denote the observed phenotypes for
the ith individual. We assume that following marginal models for the phenotype Y1
and Y2: given the genotypes of the p markers gi, we assume that y1i ∼ Bernoulli(µ1)
and y2i ∼ N(µ2, σ2), where
logit(µ1) = β0 +
∑p
i=1 giβi
µ2 = α0 +
∑p
i=1 giαi,
(4.2.1)
where α = (α0, α1, · · · , αp) and β = (β0, β1, · · · , βp) denote the parameter vectors in
the marginal models, and σ2 is the error variance. Our goal is to select the SNPs
that are associated with the secondary phenotype from the p candidate SNPs. In
other words, we aim to select the markers such that the corresponding regression
coefficients αi are non-zero.
Assuming that the joint distribution of (y1, y2) is determined by a Gaussian copula,
i.e.,
F (y1, y2) = Φ2(Φ
−1(F1(y1)),Φ−1(F2(y2)); Γ2), (4.2.2)
where Φ is the standard normal distribution, Φ2 is the standard bivariate normal
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distribution with correlation Γ2 and Fi(yi) is the cumulative distribution function
(CDF) of Yi. In our previous work (He (in revision)), we show that when the corre-
lation corr[Φ−1(F1(y1)),Φ−1(F2(y2))] between the two traits is γ(|γ| 6= 1), the density
function in cases and controls can be simplified as
f(y1, y2) =

φ(y2;µ2)(1− Φ(Φ−1(µ1)+γ(y2−µ2)√
1−γ2
)), if y1 = 0;
φ(y2;µ2)Φ(
Φ−1(µ1)+γ(y2−µ2)√
1−γ2
), if y1 = 1,
(4.2.3)
where φ is the density function of a normal random variable. The conditional proba-
bility of having disease given y2 can be easily derived as
P (y1 = 1|y2,g) = Φ(Φ
−1(µ1) + γ(y2 − µ2)√
1− γ2 ). (4.2.4)
Since the data are ascertained based on disease status, the joint retrospective likeli-
hood function for the case control samples can be written as
L =
n∏
i=1
P (y2i,gi|y1i) =
n∏
i=1
P (y1i, y2i|gi)P (gi)
P (y1i)
, (4.2.5)
where P (y1i = 1) is the disease prevalence, which is assumed to be known.
4.2.2 Penalized Likelihood Estimation
When the dimension of the genotype vector is high (p > 100), direct optimization
of the log-likelihood function (4.2.5) becomes infeasible. In addition, we expect that
there are only a few markers that are associated with the secondary phenotype Y2
and therefore the model (4.2.1) should be sparse. Instead of attempting to select the
markers that are associated with both the primary and the secondary phenotypes
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jointly, we propose a two step procedure, where in Step 1, we use the sure indepen-
dence screening (Fan and Song (2010)) or the penalized logistic regression model to
first select the markers that are associated with the primary phenotype and obtain
the parameter estimates of β. We then treat these parameters as known and focus
on variable selection for the model of the secondary outcomes.
We propose the following penalized likelihood procedure for variable selection and
for estimating the parameter α:
αˆ = argminα{Qλ(α, γ) := −l(α, γ) + λ(
p∑
j=0
|αj|)}, (4.2.6)
where l(α, γ) is the logarithm of the retrospective likelihood function, λ is a tuning
parameter that controls the degree of sparsity, and ‖α‖ = ∑pj=0 |αj| is the L1 norm.
We include α0 in this optimization procedure to simplify the computation. In practice,
we can re-scale this parameter to make it almost unpenalized.
4.3 A Coordinate Gradient Descent Method
To minimize the objective function (4.2.6), we propose to develop a profile mini-
mization approach to obtain the estimate of the association parameter γ. Specifically,
for each tuning parameter λ, we vary γ in the range [−0.5, 0.5] with an interval of 0.1
and estimate αˆ(γ) by minimizing Qλ(α, γ). We than estimate γ to be the value that
maximizes the likelihood l(αˆ(γ), γ).
For a fixed γ, the block coordinate gradient descent (CGD) method is employed
to solve the optimization problem (4.2.6) and obtain the estimate α, denoted by αˆ.
This approach is useful when the objective function consists of a smooth function and
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a block separable penalty function. The key idea of the method is to approximate
the log-likelihood by a convex quadratic and then apply block coordinate descent
to generate a descent direction (Tseng (2009)). We use the second-order Taylor
expansion l(α, γ) at αˆ and approximate Qλ(α, γ) by Mλ(d) defined as
Mλ(d) = −{l(αˆ) + dT∇l(αˆ) + 1
2
dTHd}+ λ‖αˆ + d‖1, (4.3.1)
where d ∈ Rp+1 and H is a diagonal matrix approximating the Hessian matrix.
Next we choose a nonempty index subset J ⊆ N = {0, 1, 2, ..., p} and move along
the direction dJ, where dJ is the estimated descent direction at α̂ and is defined as
dJ = argmin(Mλ(d)). Specifically, the jth component of dJ is
dj(αˆ) = −mid(∇l(αˆ)j − λ
Hjj
, αˆj,
∇l(αˆ)j + λ
Hjj
), j ∈ J, (4.3.2)
where mid(a, b, c) denotes the median or mid-point of (a, b, c).
The choice of index subject J is important for the convergence of the CGD method.
We use the Gauss-Southwell-q rule (Fletcher (1982)) to select the subset J . We define
qJ(αˆ, H) = {−dT∇l(αˆ)− 1
2
dTHd + λ‖αˆ + d‖1} − λ‖αˆ‖1, (4.3.3)
which estimates the descent in Qλ from αˆ to αˆ + d. And J is selected to satisfy
{j ∈ J |qj(αˆ, H) ≤ vminqj(αˆ, H)}, (4.3.4)
where 0 < v ≤ 1 and smaller v results in more coordinates being updated.
An inexact line search using Armijo rule (Conn (2000)) is performed for the ap-
proximate step size of the descent direction. Given αˆ and d, the step size s is the
largest value in (s0δ
l)l≥0 such that
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Qλ(αˆ + sd)−Qλ(αˆ) ≤ c0s∆, (4.3.5)
where 0 < δ < 1, 0 < c0 < 1, s0 > 0 and ∆ is the improvement in the objective
function Qλ(α, γ) when using a linear approximation for the log-likelihood and
∆ = −dT∇l(αˆ) + λ‖αˆ + d‖1 − λ‖αˆ‖1. (4.3.6)
In the implementation of the CGD method, the tuning parameters for the Gauss-
Southwell-q rule (4.3.4) are set as v[0] = 0.5,
v[t+1] =

max(10−4, v[t]/10) if s[t] > 10−3;
min(0.5, 50v[t]) else,
(4.3.7)
and the stepsize s[t] is chosen by the Armijo rule (4.3.5) with c0 = 0.1, δ = 0.5, s
[0]
0 =
1, s
[t+1]
0 = min(s
[t]/0.5, 1).
We summarize the block coordinate gradient descent optimization procedure as fol-
lowing:
Given αˆ[t],
1. Compute ∇lγ(αˆ[t]) and ∇2lγ(αˆ[t]), and let H [t] = −diag(max(∇2lγ(αˆ[t])jj, c∗)),
where c∗ > 0 is a lower bound to ensure convergence.
2. Obtain dJ(αˆ
[t]) for J = N = {0, 1, 2, ..., p}.
3. Choose a nonempty index set J [t] ⊆ N using Gauss-Southwell-q rule.
4. Set dj(αˆ
[t]) = 0 for all j /∈ J [t], and let d[t] = dJ(αˆ[t]).
5. Choose a stepsize s[t] according to Armijo rule.
6. Update αˆ[t+1] = αˆ[t] + s[t]d[t].
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The iteration is repeated until some convergence criterion is met. We stop the
interactions when the change of the likelihood functions is less than 10−5. We show
in Appendix that the objective function is convex with probability converging to 1
when the sample size goes to ∞, and therefore the algorithm converges to the global
minimum with high probability.
4.4 Choosing the Tuning Parameter λ
The Bayes information criteria (BIC) can be employed to select the tuning pa-
rameter λ that minimizes the following quantity
BIC(λ) = −2log{L(λ; γˆ, αˆ)}+ klog(n), (4.4.1)
where L(λ; γˆ, αˆ) is the value of the likelihood function with tuning parameter λ and
the estimate of γˆ and αˆ, k is the number of nonzero elements of αˆ, and n is the total
number of observations.
The BIC works well for variable selection in relatively low or moderate dimensional
settings. When p is very large, alternatively, the choice of tuning parameter λ can be
selected based on an extended Bayes information criteria (eBIC) (Chen (2008)) that
was recently developed for high dimensional settings. Specifically, we can select λ by
minimizing the following criteria,
eBIC(λ) = −2log(L(λ; γˆ, αˆ)) + klog(n) + 2γ′ log
(
p
k
)
, 0 ≤ γ′ ≤ 1, (4.4.2)
where the last term is added to the usual BIC to account for the complexity of the
model space defined by
(
p
k
)
, where p is the number of variables under consideration
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and k the size of the model. It works well when the number of covariates p is much
larger than the sample size n. Three values of γ
′
are of special interest, that is
γ
′
= 0, 0.5, 1. The value of γ
′
= 0 corresponds to the original BIC, value of γ
′
= 1
ensures consistency of eBIC when p = pn = O(n
k0) for any k0 ≥ 0 not depending on
n. The value of 0.5 ensures consistency when k0 < 1.
4.5 Simulation Studies
4.5.1 Simulation
In this section, we conduct simulations to evaluate the variable selection perfor-
mance of the proposed penalized Gaussian copula model approach in secondary trait
analysis. We simulated p = 100 SNPs with the first 5 elements of the coefficients
α being nonzero and the rest being zero. We set the minor allele frequency (MAF)
of these SNPs to be 0.3 and the regression coefficients of the secondary trait α by
controlling the heritability h2 = α
22p(1−p)
1+α22p(1−p) , which is the proportion of phenotypic
variation explained by the test SNP. We consider two sets of heritability h2 = 0.007,
which corresponds to strong association and h2 = 0.005, which corresponds to mod-
erate association. We consider three different degrees of correlation γ = 0, 0.2, 0.5.
For each scenario the 5 SNPs that are correlated with the secondary phenotype are
either associated with disease status (βi = log(1.2), i = 1..5) or not associated with
the disease status (βi = 0, i = 1..5).
To generate the binary-normal variable, we first simulate y2i from a normal distri-
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bution N(µ2, 1), where µ2 =
∑5
1 giαi, and then simulate y1i by conditional probability
y1i|y2i (Eqn 4.2.4). The case control status is determined by comparing a randomly
generated number with the conditional probability. We sample 500 cases and 500
controls for each dataset. We repeat the simulations 50 times.
4.5.2 Variable Selection
To evaluate the variable selection performance of our method, we compare re-
sults of the proposed penalized likelihood approach with those from Lasso and Lasso
adjusting the case-control status. For each method, we select the tuning parameter
using BIC, eBIC with γ
′
= 0.5 and eBIC with γ
′
= 1. For each setting, we repeat the
simulation 50 times and calculate the average number of nonzero coefficients correctly
estimated to be nonzero (denoted by C) and the average number of zero coefficients
incorrectly estimated to be nonzero (denoted by IC) over 50 simulations. The results
were summarized in Table 4.1. The false positive rate (IC) for penalized likelihood
approach and Lasso adjusting for case-control status is stable and relatively low across
all settings. Lasso tends to select more irrelevant variables especially when the cor-
relation between the primary and secondary traits is strong. In terms of correctly
selected variables (C), when OR = 1.2, Lasso performs slightly better than the pe-
nalized approach while the Lasso adjusting for the case control status performs the
worst. When OR = 1.0, the penalized approach is more efficient than the Lasso and
Lasso adjusting for case-control status. In addition, the original BIC works well in
this simulation setup in which p(100) << n(1000).
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The proposed penalized likelihood approach also out-performs the single marker
analysis when Bonferonni correction or the FDR control is used to adjust for multiple
comparisons. The single marker analysis is often conservative and leads to loss of
power for detecting the true secondary phenotype associated genetic variants.
4.5.3 Parameter Estimation
Table 4.2 presents the predictive risk R(α, αˆ) = Eα|gαˆ − gα|2 =
∑n
i=1
|gαˆ−gα|2i
n
(Foster and George (1994)) using Lasso, Lasso adjusting for the case-control status
and penalized likelihood approaches. We observe that in general the penalized likeli-
hood and Lasso adjusting for case-control status consistently have smaller predictive
risks under all the settings considered. The predictive risk using Lasso is close to the
true value when the correlation is zero. However, its predictive risk deviates from the
true value as the correlation increases, caused by the biased estimate of the intercept.
4.6 Real Data Analysis
To illustrate the effectiveness of our method in the analysis of real data, we ap-
plied the penalized likelihood approach to a genetic association study on high HDL
Cholesterol (HDL-C). HDL-C is a cross-sectional study of genetic factors contributing
to elevated HDL-C levels and is composed of subjects with extreme levels of HDL-C.
In this study, subjects of European ancestry with HDL > 90th percentile for age and
gender were considered as cases and subjects with HDL < 30th percentile for age
and gender were considered as controls. A total of 605 cases and 624 controls were
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genotyped using Affymetrix 6.0 SNP array. The primary phenotype is the HDL-C
case-control status. In addition, all study subjects have measurements on LDL-C and
separate measures on apolipoprotein concentration such as ApoB.
Our GWAS analysis revealed strong association between HDL case-control status
and a number of SNPs in gene LPL, a gene located on chromosome 8. Fig 4.1 displays
the linkage disequilibrium(LD) structure of LPL. This gene has 95 SNPs with most
SNPs not in strong LD with each other. It is well-known that LPL plays an important
role in the regulation of HDL-C level (Lettre (2011)). In our analysis, we treated LDL-
C and ApoB level as the secondary phenotypes and aimed to identify the possible
variants in this genes that are associated with these secondary phenotypes. The
analysis with single marker association did not find any association between LPL and
LDL. However, we did see strong association between LPL and ApoB.
We applied the proposed penalized likelihood approach to select the SNPs that are
associated with the secondary phenotypes. We also applied the Lasso and Lasso ad-
justing for case-control status for comparison. For the penalized likelihood approach,
we standardized each secondary phenotype by subtracting its mean estimated from
the controls and then divided by the standard deviation estimated using all samples.
Table 4.3 listed the SNPs identified to be associated with the two secondary phe-
notypes using different approaches along with the p-values from single marker asso-
ciation analysis using the copula approach (He (in revision)). For ApoB, whose level
is weakly correlated with HDL-C case control status (γ = −0.1), SNPs rs1018078 (p-
value=0.0213) and rs11994862 (p-value=0.0362) are associated with ApoB in single
marker association. However, the p-values for the two SNPs are no longer significant
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when adjusted by multiple testing. Using the approach of variable selection, Lasso
and Lasso adjusting for case-control status identified one single SNP rs1018078, Lasso
with eBIC (γ
′
= 0.5, 1) identified the same two SNPs as in single marker association
and one addition SNP rs10503670. Lasso adjusting for case-control status with eBIC
(γ
′
= 0.5, 1) identified two SNPs rs11994862 and rs10503670. The penalized likeli-
hood approach (γ
′
= 0, 0.5, 1) identified the same set of SNPs as the Lasso with eBIC
(γ
′
= 0.5, 1).
LDL-C shows a moderate correlation with HDL-C (γ = 0.15), but none of LPL
SNPs are associated with this trait in single marker association. SNPs identified in
variable selection are probably due to false discovery. From Table 4.3, one SNP was
selected by penalized likelihood approach (γ
′
= 0, 0.5, 1), Lasso and Lasso adjusting
for the case-control status. Lasso and Lasso when adjusting for the case-control status
selected two SNPs for LDL-C when eBIC (γ
′
= 0.5, 1) was used. These results indicate
that the proposed penalized likelihood approach can potentially lead to better power
of identifying the genetic variants that are associated with the secondary phenotypes.
4.7 Discussion
In this paper we have proposed a Gaussian copula model and a penalized likelihood
approach for selecting variables that are associated with the secondary phenotype in
case control genetic association study. This work is an extension of the previous work
of single marker association but allows for multiple genetic effects on the secondary
phenotypes. A tuning parameter in the penalized likelihood function is employed to
68
control the sparsity of the solution and serve the purpose of variable selection. We
performed simulations to demonstrate that our method is more efficient in selecting
variables that are associated with the secondary phenotypes than direct application of
Lasso or Lasso with adjustment of case-control status. We also demonstrated that the
penalized likelihood approach has well controlled false discovery rate when comparing
with Lasso. We have further demonstrated that penalized likelihood approach has
best sensitivity and specificity in selecting variables associated with LDL-C and ApoB
for gene LPL in a real HDL-C study.
In analysis of real data sets, we performed a two-step approach of the secondary
phenotype analysis where in step 1, we propose to apply sure independence screening
or penalized logistic regression to first identify the variants that are associated with
the primary phenotype. We then treat these variants as known in our penalized
estimation. We observed through simulation our method is very robust to the number
and specification of the loci selected in step 1. An alternative approach is to develop
methods that can identify the variants that are associated with the primary and
secondary phenotypes simultaneously.
4.8 Appendix
We verify that the Fisher’s information associated with the logarithm of the ret-
rospective likelihood function (4.2.5) is positive, which implies that the negative of
the log-likelihood function is convex with high probability when n→∞.
let x = Φ
−1(µ1)+γ(y2−µ2)√
1−γ2
let t = (y2 − µ2) + γΦ−1(µ1)
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(A) The copula model is identifiable for α0, α1.
E[
∂l
∂αi
] = E[
∂l
∂αi
|D=1] + E[ ∂l
∂αi
|D=0]
=
∫
∂l
∂αi
|D=1 × P (y = 1)dy +
∫
∂l
∂αi
|D=0 × P (y = 0)dy
=
∂µ2
∂αi
[
∫
(y − µ2)φ(y2;µ2)Φ(x)dy −
∫
γ√
1− γ2φ(x)φ(y2;µ2)dy
+
∫
(y − µ2)φ(y2;µ2)(1− Φ(x))dy +
∫
γ√
1− γ2φ(x)φ(y2;µ2)dy]
=
∂µ2
∂αi
∫
(y − µ2)φ(y2;µ2)dy
= 0
(4.8.1)
E[
∂l
∂αj
∂l
∂αk
] = E[
∂l
∂αj
∂l
∂αk
|D=1] + E[ ∂l
∂αj
∂l
∂αk
|D=0]
=
∂µ2
∂αj
∂µ2
∂αk
[
∫
(y − µ2)2φ(y2;µ2)Φ(x)dy − 2
∫
(y − µ2) γ√
1− γ2φ(x)φ(y2;µ2)dy
+
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
Φ(x)
dy] +
∂µ2
∂αj
∂µ2
∂αk
[
∫
(y − µ2)2φ(y2;µ2)(1− Φ(x))dy
+ 2
∫
(y − µ2) γ√
1− γ2φ(x)φ(y2;µ2)dy +
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
(1− Φ(x)) dy]
=
∂µ2
∂αj
∂µ2
∂αk
[1 +
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
Φ(x)(1− Φ(x))dy]
(4.8.2)
As
∂2l
∂αj∂αk
|D=1 = −∂µ2
∂αj
∂µ2
∂αk
(1 +
γ2
1− γ2 (
xφ(x)
Φ(x)
+
φ(x)2
Φ(x)2
)) (4.8.3)
∂2l
∂αj∂αk
|D=0 = −∂µ2
∂αj
∂µ2
∂αk
(1 +
γ2
1− γ2 (−
xφ(x)
1− Φ(x) +
φ(x)2
(1− Φ(x))2 )) (4.8.4)
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So
−E[ ∂
2l
∂αj∂αk
] =
∂µ2
∂αj
∂µ2
∂αk
[1 +
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
Φ(x)
dy +
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
1− Φ(x) dy]
=
∂µ2
∂αj
∂µ2
∂αk
[1 +
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
Φ(x)(1− Φ(x))dy]
(4.8.5)
Thus we have
E[
∂l
∂αj
∂l
∂αk
] = −E[ ∂
2l
∂αj∂αk
] (4.8.6)
(B) The Fisher information matrix M is positive definite. The element of M
Mj,k = E[− ∂
2l
∂αj∂αk
] =
∂µ2
∂αj
∂µ2
∂αk
[1 +
∫
γ2
1− γ2
φ(x)2φ(y2;µ2)
Φ(x)(1− Φ(x))dy] >
∂µ2
∂αj
∂µ2
∂αk
=
n∑
i=1
gi,j ×
n∑
i=1
gi,k = g
′
j × gk
(4.8.7)
The information matrix M can be written as
M =

g
′
1
g
′
2
...
g
′
p

×
(
g1 g2 ... gp
)
= G
′ ×G (4.8.8)
For all nonzero vector z,
z
′ ×M × z = z′ ×G′ ×G× z = (Gz)′ × (Gz) > 0 (4.8.9)
so M is positive definite.
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Figure 4.1: LD structure of LPL gene on chromosome 8 in the Affymetrix samples.
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Table 4.1: Simulation results - variable selection. The column labeled with C (or IC)
represents the average number of correctly (or incorrectly) identified variables and
their SEs.
C IC C IC C IC
h2 = 0.007, OR = 1.2, γ = 0.5 h2 = 0.007, OR = 1.2, γ = 0.2 h2 = 0.007, OR = 1.2, γ = 0
Lasso 3.84(0.89) 1.88(1.56) 3.12(0.90) 0.84(0.84) 2.72(0.93) 0.92(0.97)
Lasso-E.5 3.92(0.85) 2.10(1.62) 3.24(0.77) 0.88(0.85) 2.78(0.93) 1.02(0.91)
Lasso-E 3.94(0.84) 2.16(1.62) 3.30(0.81) 0.92(0.85) 2.82(0.90) 1.10(0.97)
Adjusted Lasso 1.90(0.99) 0.26(0.60) 2.12(1.12) 0.36(0.69) 2.64(0.98) 0.56(0.84)
Adjusted Lasso-E.5 2.34(0.75) 0.48(0.79) 2.48(0.93) 0.50(0.76) 2.80(0.95) 0.68(0.87)
Adjusted Lasso-E 2.38(0.75) 0.50(0.79) 2.64(0.94) 0.64(0.80) 2.86(0.95) 0.68(0.87)
Penalized copula 3.20(0.88) 0.28(0.67) 2.68(0.89) 0.30(0.58) 2.76(0.89) 0.46(0.79)
Penalized copula-E.5 3.34(0.80) 0.32(0.68) 2.92(0.72) 0.34(0.59) 2.88(0.87) 0.56(0.79)
Penalized copula-E 3.38(0.78) 0.38(0.75) 3.04(0.64) 0.42(0.64) 2.96(0.83) 0.58(0.78)
Bon-0.05 1.68(1.10) 0.04(0.20) 1.08(0.85) 0.14(0.35) 0.78 (0.79) 0.02(0.14)
FDR-0.05 2.10(1.41) 0.22(0.46) 1.42(1.05) 0.28(0.54) 1.10(1.03) 0.06(0.24)
FDR-0.10 2.64(1.41) 0.60(0.99) 1.92(1.10) 0.48(0.74) 1.80(1.41) 0.24(0.48)
h2 = 0.007, OR = 1.0, γ = 0.5 h2 = 0.007, OR = 1.0, γ = 0.2 h2 = 0.007, OR = 1.0, γ = 0
Lasso 2.38(1.03) 1.94(1.36) 2.58(1.13) 1.08(0.99) 2.50(1.07) 1.06(1.24)
Lasso-E.5 2.48(0.95) 2.06(1.24) 2.64(1.10) 1.26(0.94) 2.74(1.01) 1.22(1.23)
Lasso-E 2.52(0.97) 2.22(1.23) 2.64(1.10) 1.38(0.95) 2.78(0.97) 1.28(1.25)
Adjusted Lasso 2.50(0.99) 0.30(0.51) 2.46(1.27) 0.38(0.60) 2.50(1.25) 0.50(0.76)
Adjusted Lasso-E.5 2.72(0.83) 0.38(0.57) 2.60(1.20) 0.54(0.65) 2.76(1.13) 0.70(0.84)
Adjusted Lasso-E 2.82(0.80) 0.46(0.58) 2.66(1.19) 0.64(0.69) 2.88(1.04) 0.82(0.90)
Penalized copula 2.76(1.12) 0.60(0.81) 2.56(1.15) 0.40(0.64) 2.58(1.16) 0.58(0.93)
Penalized copula-E.5 2.98(1.00) 0.68(0.79) 2.66(1.08) 0.58(0.67) 2.72(1.09) 0.68(0.91)
Penalized copula-E 3.06(0.96) 0.76(0.77) 2.82(1.06) 0.68(0.71) 2.80(1.05) 0.84(0.98)
Bon-0.05 1.60(1.18) 0.18(0.44) 1.14(1.03) 0(0) 0.94(0.71) 0.02(0.14)
FDR-0.05 1.98(1.36) 0.44(0.73) 1.42(1.30) 0.10(0.30) 1.18(0.96) 0.14(0.53)
FDR-0.10 2.36(1.35) 0.94(1.38) 2.04(1.38) 0.28(0.57) 1.50(1.05) 0.34(0.72)
h2 = 0.005, OR = 1.2, γ = 0.5 h2 = 0.005, OR = 1.2, γ = 0.2 h2 = 0.005, OR = 1.2, γ = 0
Lasso 3.28(0.99) 1.66(1.44) 2.14(1.11) 1.10(0.95) 1.84(1.08) 0.84(0.77)
Lasso-E.5 3.34(0.96) 1.76(1.45) 2.30(1.11) 1.20(0.93) 2.10(0.91) 1.02(0.87)
Lasso-E 3.40(0.93) 1.88(1.38) 2.38(1.09) 1.32(0.89) 2.14(0.90) 1.20(0.86)
Adjusted Lasso 1.30(0.89) 0.32(0.55) 1.52(1.01) 0.54(0.68) 1.72(0.99) 0.46(0.54)
Adjusted Lasso-E.5 1.74(0.94) 0.64(0.88) 1.80(0.99) 0.84(0.87) 1.94(0.89) 0.68(0.62)
Adjusted Lasso-E 1.86(0.95) 0.70(0.93) 1.86(0.99) 0.98(0.84) 2.04(0.88) 0.72(0.64)
Penalized copula 2.44(1.11) 0.32(0.65) 1.82(0.98) 0.40(0.67) 1.98(0.96) 0.36(0.48)
Penalized copula-E.5 2.66(0.94) 0.46(0.73) 2.14(0.95) 0.62(0.75) 2.22(0.82) 0.42(0.50)
Penalized copula-E 2.68(0.96) 0.48(0.76) 2.20(0.99) 0.76(0.80) 2.38(0.78) 0.50(0.58)
Bon-0.05 0.96(0.97) 0.16(0.51) 0.50(0.54) 0.10(0.36) 0.62(0.75) 0.08(0.27)
FDR-0.05 1.12(1.13) 0.32(0.62) 0.70(0.79) 0.16(0.47) 0.72(0.93) 0.14(0.35)
FDR-0.05 1.56(1.21) 0.62(0.90) 1.02(1.10) 0.30(0.58) 1.12(1.08) 0.20(0.45)
h2 = 0.005, OR = 1.0, γ = 0.5 h2 = 0.005, OR = 1.0, γ = 0.2 h2 = 0.005, OR = 1.0, γ = 0
Lasso 1.60(1.03) 2.18(1.30) 1.72(0.90) 1.18(1.14) 1.72(1.11) 0.96(0.95)
Lasso-E.5 1.68(0.96) 2.34(1.24) 1.96(0.88) 1.42(1.07) 1.98(0.94) 1.32(1.00)
Lasso-E 1.76(0.89) 2.50(1.22) 2.04(0.83) 1.52(1.03) 2.16(1.00) 1.40(0.97)
Adjusted Lasso 1.80(0.88) 0.26(0.56) 1.62(0.81) 0.32(0.71) 1.72(1.14) 0.52(0.65)
Adjusted Lasso-E.5 2.08(0.80) 0.46(0.65) 2.10(0.84) 0.60(0.76) 2.14(1.01) 0.84(0.82)
Adjusted Lasso-E 2.24(0.87) 0.64(0.80) 2.24(0.80) 0.76(0.85) 2.28(1.01) 0.88(0.80)
Penalized copula 2.08(0.97) 0.46(0.73) 1.66(0.92) 0.44(0.73) 1.76(1.08) 0.54(0.68)
Penalized copula-E.5 2.42(0.91) 0.70(0.76) 2.20(0.78) 0.68(0.84) 2.16(0.96) 0.78(0.74)
Penalized copula-E 2.48(0.91) 0.72(0.78) 2.36(0.72) 0.80(0.86) 2.26(1.01) 0.92(0.72)
Bon-0.05 0.82(0.80) 0.08(0.27) 0.58(0.67) 0.08(0.27) 0.36(0.53) 0.04(0.20)
FDR-0.05 1.04(0.97) 0.24(0.48) 0.72(0.93) 0.16(0.37) 0.46(0.68) 0.08(0.27)
FDR-0.10 1.58(1.18) 0.62(1.00) 1.00(0.99) 0.34(0.56) 0.68(0.78) 0.20(0.40)
Lasso-E is eBIC with γ = 1 using Lasso. Adjusted Lasso-E.5 is eBIC with γ = 0.5 using Lasso adjusting for case
control status; Adjusted Lasso-E is eBIC with γ = 1 using Lasso adjusting for case control status; Penalized copula-
E.5 is eBIC with γ = 0.5 using the penalized likelihood approach; Penalized copula-E is eBIC with γ = 1 using the
penalized likelihood approach; Bon-0.05 is the single SNP analysis adjusted for Bonferroni correction; FDR-0.05 is
FDR of 0.05 based on single SNP analysis p-value; FDR-0.10 is FDR of 0.10 based on single SNP analysis p-value.
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Table 4.2: Predictive risk.
h2 = 0.007 h2 = 0.007 h2 = 0.007
OR = 1.2, γ = 0.5 OR = 1.2, γ = 0.2 OR = 1.2, γ = 0
Lasso 0.392 0.082 0.028
Lasso-E.5 0.393 0.081 0.028
Lasso-E 0.394 0.081 0.028
Adjusted Lasso 0.028 0.030 0.026
Adjusted Lasso-E.5 0.026 0.028 0.025
Adjusted Lasso-E 0.026 0.027 0.025
Penalized copula 0.018 0.024 0.023
Penalized copula-E.5 0.017 0.022 0.023
Penalized copula-E 0.017 0.022 0.023
h2 = 0.007 h2 = 0.007 h2 = 0.007
OR = 1.0, γ = 0.5 OR = 1.0, γ = 0.2 OR = 1.0, γ = 0
Lasso 0.474 0.098 0.028
Lasso-E.5 0.474 0.099 0.028
Lasso-E 0.474 0.100 0.029
Adjusted Lasso 0.023 0.026 0.027
Adjusted Lasso-E.5 0.022 0.025 0.026
Adjusted Lasso-E 0.022 0.026 0.026
Penalized copula 0.022 0.024 0.025
Penalized copula-E.5 0.021 0.024 0.024
Penalized copula-E 0.021 0.024 0.024
h2 = 0.005 h2 = 0.005 h2 = 0.005
OR = 1.2, γ = 0.5 OR = 1.2, γ = 0.2 OR = 1.2, γ = 0
Lasso 0.402 0.091 0.026
Lasso-E.5 0.402 0.091 0.026
Lasso-E 0.403 0.091 0.027
Adjusted Lasso 0.025 0.027 0.024
Adjusted Lasso-E.5 0.024 0.027 0.024
Adjusted Lasso-E 0.024 0.027 0.023
Penalized copula 0.019 0.024 0.022
Penalized copula-E.5 0.019 0.024 0.021
Penalized copula-E 0.019 0.024 0.020
h2 = 0.005 h2 = 0.005 h2 = 0.005
OR = 1.0, γ = 0.5 OR = 1.0, γ = 0.2 OR = 1.0, γ = 0
Lasso 0.468 0.099 0.029
Lasso-E.5 0.469 0.100 0.029
Lasso-E 0.469 0.100 0.029
Adjusted Lasso 0.022 0.024 0.026
Adjusted Lasso-E.5 0.022 0.023 0.026
Adjusted Lasso-E 0.022 0.024 0.025
Penalized copula 0.021 0.023 0.025
Penalized copula-E.5 0.020 0.022 0.024
Penalized copula-E 0.020 0.022 0.024
Lasso-E.5 is eBIC with γ = 0.5 using Lasso. Lasso-E is eBIC with γ = 1 using Lasso. Adjusted Lasso-E.5 is eBIC
with γ = 0.5 using Lasso adjusting for case control status; Adjusted Lasso-E is eBIC with γ = 1 using Lasso adjusting
for case control status; Penalized copula-E.5 is eBIC with γ = 0.5 using the penalized likelihood approach; Penalized
copula-E is eBIC with γ = 1 using the penalized likelihood approach.
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Table 4.3: Real data analysis results - Analysis of secondary phenotypes ApoB and
LDL-C.
ApoB coefficient P-value LDL-C coefficient P-value
Lasso rs1018078 0.110 0.0213 rs13263508 -0.0987 0.0567
Lasso-E.5 rs1018078 0.0695 0.0213 rs326 0.0793 0.0984
rs11994862 0.0523 0.0362 rs13263508 -0.0791 0.0567
rs10503670 0.0611 0.242
Lasso-E rs1018078 0.0695 0.0213 rs326 0.0793 0.0984
rs11994862 0.0523 0.0362 rs13263508 -0.0791 0.0567
rs10503670 0.0611 0.242
Adjusted Lasso rs1018078 0.109 0.0213 rs13263508 -0.0782 0.0567
Adjusted Lasso-E.5 rs1018078 0.0897 0.0213 rs13263508 -0.0811 0.0567
rs10503670 0.0677 0.242 rs10503670 0.0770 0.0835
Adjusted Lasso-E rs1018078 0.0897 0.0213 rs13263508 -0.0811 0.0567
rs10503670 0.0677 0.242 rs10503670 0.0770 0.0835
Penalized copula rs1018078 0.0682 0.0213 rs10503670 0.0749 0.0835
rs11994862 0.0492 0.0362
rs10503670 0.0675 0.242
Penalized copula-E.5 rs1018078 0.0682 0.0213 rs10503670 0.0749 0.0835
rs11994862 0.0492 0.0362
rs10503670 0.0675 0.242
Penalized copula-E rs1018078 0.0682 0.0213 rs10503670 0.0749 0.0835
rs11994862 0.0492 0.0362
rs10503670 0.0675 0.242
Lasso-E is eBIC with γ = 1 using Lasso. Adjusted Lasso-E.5 is eBIC with γ = 0.5 using Lasso
adjusting for case control status; Adjusted Lasso-E is eBIC with γ = 1 using Lasso adjusting
for case control status; Penalized copula-E.5 is eBIC with γ = 0.5 using the penalized likelihood
approach; Penalized copula-E is eBIC with γ = 1 using the penalized likelihood approach.
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Chapter 5
Conclusion
In this dissertation, we have developed new statistical methods to map genetic
variants that are associated with complex human diseases, motivated by analysis of
the high HDL candidate gene association study conducted at Penn cardiovascular
institute. In Chapter 2, we have developed a method to detect gene-gene interactions
by incorporating the external LD information obtained from the HapMap project.
This method has better power that the SNP-based tests when more than two vari-
ants interact with each other. We conducted simulations to demonstrate that tests
that incorporate external LD information are generally more powerful than those that
use genotyped markers only. This method can be applied to genome-wide association
setting and can be used as a screening tool to detect gene-gene interactions. We ex-
pect more power improvement when incorporating external information such as data
released from 1000 Genomes Project. This idea can be extended to other statistical
methods for rare variants analysis.
In Chapters 3 and 4, we have developed a Gaussian copula approach to analyze
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secondary phenotypes in case control genetic association studies. The Gaussian cop-
ula model provides a natural way of jointly modeling the secondary phenotype with
the disease status via an association parameter. When only one marker is consid-
ered in the model, we estimate the parameters using a Gauss-Newton algorithm and
perform a Wald test to access whether the marker considered is associated with the
secondary phenotype. Our model improves over the existing methods in several as-
pects. First, it allows us to correct the sampling bias of the secondary phenotype by
modeling its dependence with the primary phenotype. Second, the secondary pheno-
type does not need to have a marginal normal distribution, any phenotype from the
exponential family can be easily incorporated into the analysis. Third, this method
can be naturally extended to the analysis of multiple secondary phenotypes. Through
simulations, we have demonstrated that our method yields correct type I error rates
under a wide range of settings. Although our method is a full parametric model,
we also showed that our method is robust to model specification when the data is
simulated from Lin and Zeng’s method (Lin and Zeng (2009)).
In Chapter 4, we further consider the Gaussian copula model to include a large
number candidate SNP markers. Instead of performing a statistical test, we take a
variable selection approach to identify the genetic variants that are associated with
the secondary phenotype. We have developed a penalized likelihood approach using
the L1 penalty to select the genetic variants. We have developed an efficient coor-
dinate gradient descent algorithm to solve the optimization problem. In contrast to
single SNP analysis, this method avoids the multiple testing problem and can lead
to better power of identifying the genetic variants that are associated with the sec-
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ondary phenotypes. By using the retrospective likelihood function, our method can
also adjust for the sampling bias and result in more precise estimates of the genetic
effects on the secondary phenotypes.
In summary, we have develop several novel statistical methods for identifying
the genetic variants that are associated with complex phenotypes. The methods
presented in this dissertation provide a set of valuable tools for different statistical
analysis issues emerged in genome wide association study. Finally, we have developed
software package that is freely available.
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